...

論文(共薬ジャーナル) - 慶應義塾大学 薬学部・薬学研究科

by user

on
Category: Documents
4

views

Report

Comments

Transcript

論文(共薬ジャーナル) - 慶應義塾大学 薬学部・薬学研究科
ේ⪺⺰ᢥ
ᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯߆ࠄ⷗ߚᣣᧄߣࠝ࡯ࠬ࠻࡜࡝ࠕߦ߅ߌࠆ
⮎‛⥃ᐥ⹜㛎ߩታᣉ⁁ᴫߩᲧセ
㧙⨶ේ∛㒮ߣ Q-Pharm ࠍਛᔃߦ㧙
A CRC’s View on Conduct of Clinical Drug Study in Australia and Japan
㧙 A Comparison between Ebara Hospital and Q-Pharm 㧙
ዊᨋ ᢥ 1,2㧘ጊፒᕡ⟵ 1㧘⺪⸰ବ↵ 1
Aya Kobayashi1,2, Tsuneyoshi Yamazaki1, Toshio Suwa1
1
౒┙⮎⑼ᄢቇ⥃ᐥ⮎‛⹏ଔቇ⻠ᐳ‫ޔ‬2 ⽷࿅ᴺੱ᧲੩ㇺ଻ஜක≮౏␠⨶ේ∛㒮
1
Department of Drug Development Science and Clinical Evaluation, Kyoritsu University of Pharmacy
2
Clinical Research Center, Tokyo Metropolitan Health and Medical Treatment Ebara Hospital
(Received August 1, 2007; Revised September 20, 2007, Accepted September 27, 2007)
A comparison was made on the conduct of clinical trial at the Tokyo Metropolitan Health and
Medical Treatment Ebara Hospital in Japan and Q-Pharm Pty Limited in Australia.
The followings were pointed out as the differences of role and responsibility between CRC of
Ebara Hospital and SC of Q-Pharm..
1) The SC of Q-Pharm is actively involved in managing clinical study itself, such as organizing
study team members. The attitude of CRCs of Ebara Hospital is inclined to assist investigator rather
than manage. The CRCs also make considerable effort in coordinating functions in the hospital and
are involved in the study.
2) The coverage of CRC at Ebara Hospital is wider than that of SC of Q-Pharm. The tasks of CRC
extend from contacting to sponsor before the contract is signed, complementary explanation of the
study to recruited study subjects, participation to study audit. The main tasks of SC start from
initiation of a study. The SC does not get involved in obtaining the informed consent from study
subjects.
3) The role and responsibility of SC of Q-Pharm is described in the job description, whereas, no
job description is available for CRC of Ebara Hospital.
4) It is presumed that the clarification of the job of CRC in Japanese study sites will lead to the
improvement of efficiency of clinical study conduct.
✜⸒
౒ㅢߥ᳓Ḱࠍ⛽ᜬߒߡታᣉߐࠇࠆߎߣߣߥߞߚ‫ޕ‬
ICH-GCP એ㒠‫ޔ‬਎⇇⊛ߦߪ⮎‛ߩ⥃ᐥ⹏ଔ⹜㛎
‫޿⦟ࠅࠃޟ‬ක⮎ຠࠍࠃࠅᣧߊᖚ⠪ߩర߳㧍‫޿ߣޠ‬
ߪᄙ࿖㑆࡮ᄙᣉ⸳ߦࠃࠆ⹜㛎‫࡞ࡃ࡯ࡠࠣࠆࠁࠊ޿ޔ‬
߁਎⇇౒ㅢߩ㗿޿ࠍ㆐ᚑߐߖࠆߚ߼ߦ ICH ߇ࠬ
ᴦ㛎߇Ⴧടߔࠆ௑ะߦ޽ࠆ‫৻ߩߘߒ߆ߒޕ‬ᣇ‫ޔ‬ᣣᧄ
࠲࡯࠻ߒߡ߆ࠄᣢߦ 15 ᐕએ਄߇⚻ㆊߒߚ‫߇ࠊޕ‬࿖
ߩᴦ㛎ߪ‫ޠ࠻ࠬࠦޟ‬
‫ޔ‬
‫ᤨޟ‬㑆‫ޔޠ‬
‫ߩޠ⾰ޟ‬㕙ߢߩ໧㗴ࠍ
ߦ߅޿ߡߪ 1997 ᐕߦ ICH-GCP ߦၮߠ޿ߚ‫ޟ‬ක⮎ຠ
ᜰ៰ߐࠇ‫࡞ࡃ࡯ࡠࠣ߆ߥ߆ߥޔ‬ᴦ㛎ߩખ㑆౉ࠅ߇ߢ
ߩ⥃ᐥ⹜㛎ߩታᣉၮḰ㧔޿ࠊࠁࠆ J-GCP㧕‫߇ޠ‬ᴺ೙
߈ߦߊ޿ߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬
ൻߐࠇ‫ޔ‬એᓟߩᣂ⮎ߩ⥃ᐥ⹏ଔ㧔ᴦ㛎㧕ߪ਎⇇⊛ߦ
1/12
╩⠪㧔ዊᨋ‫ޔ‬એᓟ╩⠪㧕ߪ‫⃻ޔ‬࿷‫⽷ޔ‬࿅ᴺੱ᧲੩
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
39
Kobayashi A et al.
ㇺ଻ஜක≮౏␠⨶ේ∛㒮㧔એᓟ‫ޔ‬
‫⨶ޟ‬ේ∛㒮‫ޠ‬㧕ߢᴦ
CRC ߩታോࠍਛᔃߦ⺞ᩏߒߚ‫ⷰߡߒߘޕ‬ኤ࡮⺞ᩏ
㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧔એᓟ‫ޟ‬CRC‫ޠ‬㧕ᬺോߦᓥ੐ߒ
ߩ⚿ᨐࠍ⨶ේ∛㒮ߦ߅ߌࠆᴦ㛎ታᣉ⁁ᴫߣᲧセߒ
ߡ޿ࠆ⮎೷Ꮷߢ޽ࠆ‫ޕ‬ᴦ㛎ᬺോߦ៤ࠊࠆ CRC ߪో
ߚ‫࠼ࡦ࡜࠭ࡦ࡯ࠗࠢޕ‬ᄢቇ߳ߩṛ࿷ᦼ㑆ߪᐔᚑ 19
ຬ GCP ߩ♖␹ߣታോࠍࠃߊℂ⸃ߒߟߟᣂ⮎ߩ⥃ᐥ
ᐕ 1 ᦬߆ࠄ 3 ᦬߹ߢߩ 3 ࡩ᦬㑆ߢ޽ߞߚ‫ޔߦᦝޕ‬ṛ
⹜㛎㧔ᴦ㛎㧕ߦขࠅ⚵ߺ‫ߩ⾰ޔ‬㜞޿⥃ᐥ࠺࡯࠲ࠍ෼
࿷⚳ੌᓟߦਇ⿷ߔࠆᖱႎࠍ Q-Pharm ߆ࠄㅊട౉ᚻ
㓸ߔߴߊᣣ‫ޘ‬ദജߒߡ޿ࠆ‫ޔߕࠄࠊ߆߆߽ߦޕ‬ᣣᧄ
ߒߚ‫ޕ‬૬ߖߡ‫ޔ‬ᢥ₂ᬌ⚝ߦࠃࠅࠝ࡯ࠬ࠻࡜࡝ࠕߩ
ߩᴦ㛎ߪᶏᄖ߆ࠄߩᛕ್ࠍฃߌ‫ޔ‬࿖㓙ᴦ㛎ߦෳടߒ
CRC ߩᢎ⢒߿ታോ⁁ᴫߦ㑐ߔࠆᖱႎࠍ౉ᚻߒߚ‫ޕ‬
ߦߊ޿ߣ޿߁⃻⁁ߦ㆑๺ᗵࠍᜬߞߡ޿ࠆ‫ޟޕ‬૗᡿ᣣ
ᧄߩᴦ㛎߇ᶏᄖ߆ࠄߘߩࠃ߁ߦૐ޿⹏ଔࠍฃߌࠆ
ߩߛࠈ߁㧫‫⇼߁޿ߣޠ‬໧ߣหᤨߦ‫ߪߢࠇߘޟޔ‬ᶏᄖ
⚿ᨐ
ߩᴦ㛎ߣᣣᧄߩᴦ㛎ߢߪ⠨߃ᣇ߿ታᣉ㕙ߢ৻૕ߤ
ߩࠃ߁ߥ㆑޿߇޽ࠆߩߛࠈ߁߆㧫‫╩ߦߣߎ߁޿ߣޠ‬
1㧚ࠝ࡯ࠬ࠻࡜࡝ࠕߩ⥃ᐥ⎇ⓥⅣႺߣ Q-Pharm
⠪ߪ⥝๧߽ᜬߟࠃ߁ߦߥߞߚ‫⑼⮎┙౒ߡߒߘޕ‬ᄢቇ
ߩ┙࿾࡮⸳஻⁁ᴫ
ߦ␠ળੱᄢቇ㒮↢ߣߒߡ౉ቇߒ‫੹ޔ‬࿁‫ޔ‬࿖㓙ᴦ㛎ߩ
ࠝ࡯ࠬ࠻࡜࡝ࠕߪੱญ⚂ 2000 ਁੱߩ࿖ߢ޽ࠆ‫ޕ‬
⚻㛎⼾߆ߥࠝ࡯ࠬ࠻࡜࡝ࠕߩࡉ࡝ࠬࡌ࡯ࡦᏒߦ޽
߆ߟߡߪ⧷࿖ߩ⛔ᴦਅߦ޽ߞߚߚ߼ක≮ࠍ฽߻ᄙ
ࠆࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᄢቇ㑐ㅪߩ⥃ᐥ⹜㛎ฃ⸤ᣉ⸳
ߊߩಽ㊁ߢ⧷࿖ߩᢥൻ߿ᘠ⠌ߩᓇ㗀ࠍᒝߊฃߌߡ
Q-Pharm Pty Limited㧔એᓟ‫ޟ‬Q-Pharm‫ޠ‬㧕ߢ⮎‛⥃ᐥ
޿ࠆ‫⃻ޕ‬࿷ߩਥⷐߥ↥ᬺߪ㋶ᬺߣㄘᬺߢ޽ࠆ߇‫ޔ‬ㄭ
⎇ⓥߩታോࠍⷰኤ࡮⺞ᩏߔࠆᯏળࠍᓧߚ‫ޕ‬
ᐕߎߩ࿖ߩ↥ᬺߩ 3 ⇟⋡ߩᩇߦߔߴߊࡃࠗࠝࠨࠗ
ᧄⷰኤ࡮⺞ᩏߩ⋡⊛ߪᰴߩ 3 ὐߢ޽ࠆ‫ޕ‬
ࠛࡦࠬߦജࠍ౉ࠇߡ޿ࠆ‫ޕ‬࿖ౝߦഃ⮎߇น⢻ߥⷙᮨ
Ԙ ࠝ࡯ࠬ࠻࡜࡝ࠕߦ߅ߌࠆ⮎‛ߩ⥃ᐥ⹏ଔ⹜㛎
ߩ⵾⮎ડᬺߪᧂߛሽ࿷ߖߕ‫ޔ‬ᄙߊߩᣂ⮎ߪ⷏᰷ߩᄢ
⵾⮎ડᬺ߆ࠄଏ⛎ߐࠇߡ޿ࠆ‫৻ޕ‬ᣇ‫ࠛࠗࠨࠝࠗࡃޔ‬
ߩታോࠍ⚻㛎ߔࠆߎߣ
ԙ ᣣᧄߣࠝ࡯ࠬ࠻࡜࡝ࠕߩ⥃ᐥ⹜㛎ߦ߅ߌࠆ
ࡦࠬߩಽ㊁ߦߪᄢቇ⊒ߩࡌࡦ࠴ࡖ࡯ડᬺߪᢙᄙߊ
ሽ࿷ߔࠆ‫ޕ‬
CRC ߩᓎഀߣታോౝኈࠍᲧセߔࠆߎߣ
Ԛ Ყセᬌ⸛ߩ⚿ᨐߦၮߠ߈ CRC ߩⷰὐ߆ࠄᣣᧄ
ࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᄢቇߪࠝ࡯ࠬ࠻࡜࡝ࠕߩ᧲ർ
ߩᴦ㛎ߩല₸ൻߣࠣࡠ࡯ࡃ࡞ᴦ㛎߳ߩෳ౉ߩ
ㇱߦ૏⟎ߔࠆࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᎺߩᎺㇺࡉ࡝ࠬ
ᚻ┙ߡࠍᮨ⚝ߔࠆߎߣ
ࡌ࡯ࡦ㧔ੱญ⚂ 150 ਁੱ㧕ߦ޽ࠆቇ↢ᢙ⚂ 3 ਁ 5 ජ
ੱߩᎺ┙✚วᄢቇߢ޽ࠆ‫࡝ࡉߪࠬࡄࡦࡖࠠࡦࠗࡔޕ‬
ࠬࡌ࡯ࡦᏒߩ࠳࠙ࡦ࠲࠙ࡦ߆ࠄ߿߿ౝ㒽஥ߦ૏⟎
ᣇᴺ
ߔࠆ࠮ࡦ࠻࡮࡞ࠪࠕ㧔St.Lucia㧕ߦ޽ࠆ߇‫ޔ‬කቇㇱ
ߩ৻ㇱߣ㑐ㅪ∛㒮ᣉ⸳ߪ࠳࠙ࡦ࠲࠙ࡦ߆ࠄࡃࠬߢ
౒┙⮎⑼ᄢቇߪᢥㇱ⑼ቇ⋭߇൐㓸ߒߚᄢቇᢎ⢒
20 ಽ߶ߤߩᏒౝߦ޽ࠅ‫ࡦ࡯ࡌࠬ࡝ࡉ࡮࡞ࡗࠗࡠޔ‬
ᡷ㕟੐ᬺ‫ޟ‬㝯ജ޽ࠆᄢቇᢎ⢒㧔޿ࠊࠁࠆᄢቇ㒮 GP㧕
‫ޠ‬
෸߮↥⑼∛㒮⟲㧔The Royal Brisbane and 㨃omen’s
ࠗ࠾ࠪࠕ࠴ࡉߦᔕ൐ߒ‫ޟޔ‬࿖㓙ᕈߣ⎇ⓥ⢻ജࠍ஻߃
Hospitals‫ޔ‬એᓟ RBH ∛㒮⟲㧕ߣ๭߫ࠇࠆᄢ߈ߥ∛
ߚ⥃ᐥ⮎೷Ꮷߩ⢒ᚑ㧔ᐔᚑ 18~19 ᐕᐲ㧕‫࡜ࠣࡠࡊޠ‬
㒮ᣉ⸳⟲ࠍᒻᚑߒߡ޿ࠆ‫∛ߩߎޕ‬㒮⟲ߩਛᩭߢ޽ࠆ
ࡓ߇ណᛯߐࠇߚ‫╩ޕ‬⠪ߪߎߩᄢቇ㒮 GP ߩᡰេࠍฃ
ࡠࠗࡗ࡞࡮ࡉ࡝ࠬࡌ࡯ࡦ෸߮↥⑼∛㒮ߪࡌ࠶࠼ᢙ
ߌߡࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᄢቇකቇㇱ⮎‛ઍ⻢⎇ⓥᚲ
948 ᐥࠍᜬߟ߇‫ޔ‬㓞ធߔࠆࡠࠗࡗ࡞ዊఽ∛㒮㧔The
㧔 Center for Studies in Drug Disposition ‫ ޔ‬એ ਅ
Royal Children Hospital‫࠼࠶ࡌޔ‬ᢙ 160㧕߽೎ߩ⁛┙
‫ޟ‬CSDD‫ޠ‬㧕ߦ☋ࠍ⟎߈‫ޔ‬ᄢቇߦ㑐ㅪߒ‫ޔ‬㓞ធߔࠆ
ߒߚ∛㒮ߣߒߡㆇ༡ߐࠇߡ޿ࠆ‫╩ޔߚ߹ޕ‬⠪߇☋ࠍ
⥃ᐥ⹜㛎ฃ⸤ᯏ㑐 Q-Pharm ߢ⥃ᐥ⹜㛎ߩታᣉ⁁ᴫ
߅޿ߚࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᄢቇකቇㇱ CSDD ߅ࠃ߮
ࠍ⺞ᩏߒߚ‫⺞ޕ‬ᩏߪ⹜㛎ᣉ⸳ߩ᭎ⷐ‫⹜ޔ‬㛎ታᣉߩ⁁
Q-Pharm ߽ߎߩ∛㒮⟲ౝߦ޽ࠆ‫ޕ‬
ᴫ‫⹜ޔ‬㛎ታᣉߩߚ߼ߩ⻉ᢥᦠߥߤߦ෸ࠎߛ߇‫ߦ․ޔ‬
40
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
2/12
╩⠪߇ታോ⺞ᩏࠍⴕߞߚ Q-Pharm ߪ RBH ∛㒮⟲
原著論文
౮⌀ 3 Q㧙Pharm ࠬ࠲࠶ࡈߣ╩⠪
౮⌀ 1 Q㧙Pharm㧔1.6 㓏㧕
౮⌀ 4 ᴦ㛎࡞࡯ࡓ
ࠕ࡯ࠞࠗࡉߥߤߢ޽ࠆ‫߽ࠇߕ޿ޕ‬චಽߥࡈࡠࠕ㕙Ⓧ
ࠍ߽ߜ‫ߚߒߣࠅߚߞࠁޔ‬㔓࿐᳇߇޽ࠆ‫ޕ‬
ஜᏱⵍ㛎⠪ኻ⽎ߩࠢ࡝࠾࠶ࠢߪਛᄩߦ⹜㛎࠴࡯
ࡓ↪ߩࡉ࡯ࠬ߇⟎߆ࠇ‫ⵍޔ‬㛎⠪↪ߩࡌ࠶࠼ߪߘߩ
౮⌀ 2 ࡉ࡝ࠬࡌࡦߩⴝਗߺ
ࡉ࡯ࠬࠍ࿐߻ࠃ߁ߦࠦߩሼဳߦ㈩⟎ߐࠇߡ޿ࠆ‫ޕ‬ㇱ
ደߩోߡߩᩇߦᄢ߈ߥᤨ⸘߇߆ߌࠄࠇߡ߅ࠅ‫ߩߤޔ‬
ౝߦ޽ࠆ࡜ࡏ࡜࠻࡝࡯ߣࠢ࡝࠾࠶ࠢࠍ૬ߖᜬߟ⥃
ⵍ㛎⠪߽ኈᤃߦ⥄ಽߢࠬࠤࠫࡘ࡯࡞▤ℂ߇ߢ߈ࠆ
ᐥ⮎ℂ⹜㛎ฃ⸤ળ␠ߢ޽ࠆ‫ޕ‬ฃ⸤น⢻ߥ⹜㛎ߪ╙Σ
ࠃ߁㈩ᘦߐࠇߡ޿ࠆ‫ⵍޔߚ߹ޕ‬㛎⠪߇࡝࡜࠶ࠢࠬߢ
⋧⥃ᐥ⹜㛎‫‛↢ޔ‬ቇ⊛ห╬ᕈ⹜㛎‫․ޔ߮ࠃ߅ޔ‬ቯߩ
߈ࠆࠃ߁ߦ⹜㛎ቶߩ৻ⷺߦߪ࠰ࡈࠔ࡯ࠍ஻߃ߚભ
∔ᖚᖚ⠪ߦࠃࠆ⥃ᐥ⮎ℂ⹜㛎ߢ޽ࠆ߇‫ޔ‬ታᣉߒߡ޿
ᕷቶ߇޽ࠅ࠹࡟ࡆ߿ᦠ‛߇߅߆ࠇߡ޿ࠆ‫ޕ‬
ࠆᄙߊߩ⹜㛎ߪ↢‛ቇ⊛ห╬ᕈ⹜㛎ߢ޽ࠆ‫ޕ‬
Q-Pharm ߦߪ✚൓ 100 ฬࠍ⿥߃ࠆࠬ࠲࠶ࡈ߇ൕോ
ࠝ࡯ࠬ࠻࡜࡝ࠕߪ↥ᬺᝄ⥝ߦᾲᔃߢ޽ࠅ‫ޔ‬᡽╷⊛
ߒߡ޿ߚ‫ޕ‬㓹↪ᒻᘒߪᱜ␠ຬ‫ޔ‬㕖Ᏹൕ␠ຬ‫ⷐᤨ⥃ޔ‬
ߦᄢቇ⊒ࡌࡦ࠴ࡖ࡯ડᬺߩ⢒ᚑࠍ࿑ߞߡ޿ࠆ߇‫ޔ‬
ຬߩ 3 ⒳ߦಽ߆ࠇߡ޿ߚ‫࡞ࠞࠖ࠺ࡔߪߦ⊛❱⚵ޕ‬ㇱ
Q-Pharm ߽ࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᄢቇකቇㇱ CSDD ߆
㐷‫ࠢ࠶࠾࡝ࠢޔ‬ㇱ㐷‫ޔ‬ಽᨆㇱ㐷‫✚ޔ‬ോㇱ㐷
ࠄࠬࡇࡦࠕ࠙࠻ߒߚࡌࡦ࠴ࡖ࡯ડᬺߩ㧝ߟߢ޽ࠆ‫ޕ‬
㧔Administration㧕‫ޔ‬෸߮ຠ⾰଻⸽ㇱ㐷ߦಽ߆ࠇߡ߅
CSDD ߢߪએ೨߆ࠄડᬺ߆ࠄฃ⸤ߒߡ⮎‛േᘒ⹜
ࠅ‫࡞ࠞࠖ࠺ࡔޔ‬ㇱ㐷ߪ⹜㛎⽿છකᏧ 4 ฬ㧔޿ߕࠇ߽
㛎߿⥃ᐥ⮎ℂ⹜㛎ࠍታᣉߒߡ߈ߚ߇‫ޔ‬2002 ᐕߦฃ
㕖Ᏹൕ㧕ߣ⮎೷Ꮷ 2 ฬ㧔1 ฬߪᱜ␠ຬ‫ ઁޔ‬1 ฬߪ㕖
⸤⹜㛎ߩㇱಽࠍಾࠅ㔌ߒ‫ޔ‬ቇౝߦ Q-Pharm ࠍ⸳┙
Ᏹൕߩ੤ઍⷐຬ㧕ߢ᭴ᚑߐࠇߡ޿ߚ‫ޕ‬ᣣᧄߩ CRC
ߒߚ‫ޕ‬Q-Pharm ߪ㧝ߟߩ∛㒮ࡆ࡞ߩ 2 ࡈࡠࠕࠍභ߼
ߦ⋧ᒰߔࠆࠬ࠲࠺ࠖ࡯࡮ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧔study
ߡ߅ࠅ‫✚ߩߘޔ‬ᐥ㕙Ⓧߪ⚂ 3,000 ᐔᣇࡔ࡯࠻࡞ߢ
coordinator‫ޔ‬એᓟ‫ޟ‬SC‫ޠ‬㧕ߪࠢ࡝࠾࠶ࠢㇱ㐷ߦᚲዻ
޽ߞߚ‫ޕ‬ਥⷐߥ⸳஻ߪஜᏱⵍ㛎⠪ኻ⽎ߩ 36 ࡌ࠶࠼
ߒ‫ߩߘޔ‬ᢙߪ 15 ฬ‫ߩߎޕ‬ㇱ㐷ߦߪઁߦࡑࡀࠫࡖ࡯5
ߩᄢ߈ߥ⥃ᐥ⹜㛎ቶ‫⥃ޔ‬ᐥ⮎ℂ⎇ⓥ↪ߦฦ⒳ߩ᷹ቯ
ฬ‫࠻࡯࡞ࠢ࡝ޔ‬ᜂᒰ 5 ฬ‫ ࠻ࡦࡔࠫࡀࡑ࡯࠲࡯࠺ޔ‬5
ࡕ࠾࠲࡯ᯏེࠍ஻߃ߚ୘ቶ‫ޔ‬ಽᨆ࡜ࡏ‫⺞ޔ‬೷࡜ࡏ‫ޔ‬
ฬ߅ࠃ߮⚂ 50 ฬߩ⥃ᤨⷐຬ߇ᚲዻߒߡ߅ࠅ‫⹜ޔ‬㛎
3/12
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
41
Kobayashi A et al.
ߩታᣉ߇ਥോߢ޽ߞߚ‫ޕ‬ಽᨆ࡜ࡏߩⷐຬߪࡑࡀ
߿ GCP ࠍ฽߻ක⮎ຠߩ⎇ⓥ㐿⊒ߦ㑐ߔࠆᢎ⢒߇฽
ࠫࡖ࡯2 ฬߣᛛⴚ⠪ 13 ฬߢ޽ߞߚ‫ࠖ࠺ࡔޔߚ߹ޕ‬
߹ࠇߡ޿ࠆ߇‫࠼ࡦ࡜࠭ࡦ࡯ࠗࠢޔ‬ᄢቇ⮎ቇㇱߩᢎ⢒
ࠞ࡞࡜ࠗ࠲࡯2 ฬߪ✚ോㇱ㐷ߦᚲዻߒ‫ޔ‬ຠ⾰଻⸽ㇱ
ࠞ࡝ࠠࡘ࡜ࡓߪ᰷☨⻉࿖ߣห᭽ߦ⮎೷Ꮷ㙃ᚑࠍਛ
㐷ߪࡑࡀࠫࡖ࡯1 ฬߣࠕࠪࠬ࠲ࡦ࠻ 1 ฬߢ޽ߞߚ‫ޕ‬
ᔃߣߒߚᢎ⢒ߢ޽ࠅ‫ޔ‬ක⮎ຠ㐿⊒߿ᣂ⮎ߩ⥃ᐥ⎇ⓥ
␠㐳ߩ Professor Wayne Hooper ߪࠢࠗ࡯ࡦ࠭࡜ࡦ
ߪᱴߤ฽߹ࠇߥ޿‫ߩߎߪߣߎߩߎޕ‬࿖ߢ⮎ቇ಴りߩ
࠼ᄢቇᢎ᝼ߩ⢋ᦠ߈߽ᜬߟ‫ޕ‬એ೨ߪหᄢቇකቇㇱ
CRC ߇⊝ήߦ╬ߒ޿ߎߣߩ㧝ߟߩℂ↱ߢ޽ࠆߣᕁ
CSDD ߦᚲዻߒߚ⎇ⓥ⠪ߢ޽ߞߚ‫ߩࡦࠗ࠻࠾ࠚࡈޕ‬
ࠊࠇࠆ‫⮎ߪߢࡦ࡯ࡌࠬ࡝ࡉޕ‬ቇ↢߿⮎೷Ꮷ߆ࠄ SC
ᶖൻ▤ๆ෼߇⵾೷ߩᷝട‛ࠍ੃♧߆ࠄ⎫㉄ࠞ࡞ࠪ
ࠍ߿ࠅߚ޿ߣ޿߁Ꮧᦸߪ⡞߆ࠇߥ޿‫ޕ‬
࠙ࡓߦᄌ߃ࠆߎߣߦࠃࠅ⪺ߒߊᷫዋߔࠆߣ޿߁ᓐ
╩⠪߇ൕ߼ࠆ⨶ේ∛㒮ߩ CRC ߣ Q-Pharm ߩ SC
ߩ⊒⷗ߪ↢‛⮎೷ቇߩಽ㊁ߢߪࠃߊ⍮ࠄࠇߚᬺ❣
ߩ․ᕈࠍ⴫㧝ߦᲧセߒߡ␜ߒߚ‫ޕ‬CRC ᢎ⢒ߦ㑐ߒ
1㧕
ߡߪᣣᧄ‫⮎ߦ౒ࠕ࡝࡜࠻ࠬ࡯ࠝޔ‬೷Ꮷ߿⋴⼔Ꮷᢎ⢒
ߢ޽ࠆ ‫ޕ‬
ߩਛߦขࠅ౉ࠇࠄࠇߡߪ޿ߥ޿‫ޕ‬ਔ࿖ߣ߽ CRC ߣ
2. ࠬ࠲࠺ࠖ࡯࡮ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧔SC㧕ߣߘߩ
ߒߡߩኾ㐷ᢎ⢒ࠍතᓟߦฃߌߡ޿ࠆ‫ޕ‬CRC ᢎ⢒ߩ
ᬺോ
႐ߣߒߡᣣᧄߢߪᣣᧄ⮎೷Ꮷ⎇ୃ࠮ࡦ࠲࡯‫ޔ‬ᣣᧄ⥃
ᣣᧄߢߪࠢ࡝࠾ࠞ࡞࡮࡝ࠨ࡯࠴࡮ࠦ࡯࠺ࠖࡀ࡯
ᐥ⮎ℂቇળ‫ޔ‬ᣣᧄ∛㒮⮎೷Ꮷળ‫ޔ‬SoCRA‫ޔ‬ᣣᧄ⋴
࠲࡯㧔CRC㧕ߣ๭߫ࠇࠆ⡯⒳ࠍ Q-Pharm ߢߪࠬ࠲
⼔දળ‫ޔ‬ᣣᧄකᏧળߥߤ߇⎇ୃࠦ࡯ࠬࠍ⸳ߌߡ߅
࠺ࠖ࡯࡮ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧔SC㧕ߣ๭ࠎߢ޿ߚ‫ޕ‬
ࠅ‫ޔ‬ฃ⻠⚳ੌ⠪ߦߪ⹺ቯ⸽ࠍ⊒ⴕߒߡ޿ࠆ‫߹ޕ‬
࿃ߺߦ‫ޟޔ‬CRC‫ߡ޿ߟߦޠ‬዆ߨߡߺߚ߇‫߁޿߁ߘޔ‬
ߚ‫ޔ‬ਥⷐߥ SMO ߪ⥄␠ౝߦ CRC ᢎ⢒ࠦ࡯ࠬࠍ⸳
๭⒓ߪ⍮ࠄߥ޿ߣ޿߁㄰੐߇㄰ߞߡ߈ߚ‫ޕ‬
ߌߡ޿ࠆ‫ߢࡦ࡯ࡌࠬ࡝ࡉޕ‬ᓧߚᖱႎߦࠃࠇ߫‫☨ޔ‬࿖
Q-Pharm ߩ SC ߪోຬ⋴⼔Ꮷߢ޽ࠆ‫ޕ‬ᣣᧄߩ CRC
ߣ᰷Ꮊߦᧄ᜚ࠍ⟎ߊ Association of Clinical Research
ߪ⋴⼔Ꮷ‫⮎ޔ‬೷Ꮷ‫⥃ޔ‬ᐥᬌᩏᛛᏧߩ޿ߕࠇ߆ߩ⾗ᩰ
Professionals㧔ACRP㧕ߦࠃࠆ CRC ⎇ୃࠦ࡯ࠬ߇㐿
⠪ߢ޽ࠆߩߣߪᄢ߈ߥ㆑޿ߢ޽ࠆ‫ޕ‬Q-Pharm ߩ SC
⻠ߐࠇߡ߅ࠅ‫ࠍࠬ࡯ࠦߩߎޔ‬ฃߌߡߩߜ SC ᬺോߦ
ߦ‫⮎ޟ‬೷Ꮷߩ⾗ᩰࠍᜬߟ SC ߪ޿ߥ޿ߩ߆㧫‫ߣޠ‬዆
ᓥ੐ߔࠆ⠪߇޽ࠆ‫ޕ‬
⴫ 2 ߦ Q-Pharm ߩ SC ߩ⡯ോ⸥ㅀᦠࠍ␜ߒߚ‫⨶ޕ‬
ߨߚߣߎࠈ‫ޔ‬
ㅒߦ‫ޔ‬
‫ޟ‬૗᡿⮎೷Ꮷ߇ SC ࠍ߿ࠆߩ߆㧫‫ޠ‬
ߣ޿߁⾰໧߇㄰ߞߡ߈ߚ‫⮎ߢࠕ࡝࡜࠻ࠬ࡯ࠝޕ‬೷Ꮷ
ේ∛㒮ߦߪ CRC ߦኻߔࠆߎߩࠃ߁ߥ⡯ോ⸥ㅀᦠߪ
߇ SC ᬺോߦዞ߆ߥ޿ߎߣߩℂ↱ߪ޿ߊߟ߆޽ࠆߛ
ߥ޿‫ޕ‬⡯ോ⸥ㅀᦠߩౝኈߪ SC ߩ‫ޟ‬Position Purpose‫ޠ‬
ࠈ߁‫ޕ‬ᣣᧄߩ⮎♽ᄢቇߩᢎ⢒ࠞ࡝ࠠࡘ࡜ࡓߦߪᴦ㛎
ߣ‫ޟ‬Major Responsibility Areas‫ ߩߣޠ‬2 ߟߦಽ߆ࠇߡ
⴫ 1㧦⨶ේ∛㒮ߩ CRC ߣ Q-Pharm ߩ SC ߩ․ᕈᲧセ
㗄⋡
⾗ᩰ㧔ᢎ⢒㧕
CRC ߩᢎ⢒
⨶ේ∛㒮
Q-Pharm
⋴⼔Ꮷ‫⮎ޔ‬೷Ꮷ
⋴⼔Ꮷ
⻉࿅૕ߦࠃࠆᢎ⢒ࠦ࡯ࠬ
Association of Clinical Research Professionals ᵈ 2
㧔ᣣᧄ⥃ᐥ⮎ℂቇળ‫ޔ‬ᣣᧄ∛㒮⮎೷Ꮷળ‫ޔ‬
(ACRP)߇㐿⻠ߒߡ޿ࠆᢎ⢒ࠦ࡯ࠬ
SoCRA ᵈ 1‫ޔ‬ᣣᧄ⋴⼔දળ‫ޔ‬ᣣᧄකᏧળ߇㐿⻠㧕
CRC ߩ⾗ᩰ೙ᐲ
ฦ࿅૕߇ฃ⻠⚳ੌ⠪ߦ‫⹺ޟ‬ቯ⸽‫ⴕ⊒ࠍޠ‬
ACRP ߇ Certificate ࠍ⊒ⴕ
╙ II‫ޔ‬III ⋧⹜㛎
╙ I‫ޔ‬II ⋧⹜㛎
ᬺോߩ▸࿐
⵾ㅧ⽼ᄁᓟ⥃ᐥ⹜㛎
↢‛ቇ⊛ห╬ᕈ⹜㛎
㧔⥃ᐥ⹜㛎ߩ⒳㘃㧕
Ꮢ⽼ᓟ૶↪ᚑ❣⺞ᩏ‫ޔ‬Ꮢ⽼ᓟ૶↪ో଀⺞ᩏ
⮎‛േᘒ⹜㛎
කᏧਥዉߩ⥃ᐥ⹜㛎
⥃ᐥ⮎ℂ⹜㛎
᧲੩ㇺਥዉߩ⥃ᐥ⎇ⓥ
ᵈ 1㧦SoCRA㧦The Society of Clinical Research Associate, Inc.)‫ᧄߦࠞ࡝ࡔࠕޕ‬᜚ࠍ⟎ߊ⥃ᐥ⹜㛎ኾ㐷⡯㧔ࠢ࡝࠾ࠞ࡞࡮࡝ࠨ࡯࠴࡮ࠦ࡯࠺ࠖࡀ࡯࠲࡯‫࡮࡞ࠞ࠾࡝ࠢޔ‬
࡝ࠨ࡯࠴࡮ࠕ࠰ࠪࠛ࡯࠻‫ߤߥ࡯ࡖࠫࡀࡑ࡯࠲࡯࠺ޔ‬㧕ࠍ㙃ᚑߔࠆ㕖༡೑࿅૕‫ޕ‬ᣣᧄᡰㇱߪ 2002 ᐕߦ⸳┙ߐࠇߚ‫⃻ޕ‬࿷਎⇇ߦ 48 ᡰㇱ߇޽ࠆ‫ޕ‬
ᵈ 2㧦ACRP ߪ Association of Clinical Research Professionals ߩ⇛‫ޕ‬ක⮎ຠ‫‛↢ޔ‬ቇ⊛⵾೷‫ޔ‬ක≮ᯏེߥߤߩ⥃ᐥ⎇ⓥߦᓥ੐ߔࠆᛛⴚ⠪ࠍ㙃ᚑߔࠆ࿅૕ߣߒߡ 1976
ᐕ☨࿖ߦ⸳┙ߐࠇߚ‫☨ޕ‬࿖ߣ᰷Ꮊߦᧄ᜚ࠍᜬߟ߇‫߽ߦࠕ࡝࡜࠻ࠬ࡯ࠝޔ‬ᡰᚲࠍ⟎޿ߡ޿ࠆ‫ޕ‬
42
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
4/12
原著論文
⴫ 2㧦Q-Pharm ߩ SC ߩ⡯ോ⸥ㅀᦠ
Position Purpose:
a. To carry out clinical trial research contributing to better clinical management.
b. To aid/assist supervisors to perform correct clinical trial practice and monitoring
Major Responsibility Areas:
a. To co-ordinate and assist in the execution of trials
b. Maintain accurate patient data and ensure completion of CRF
c. Collection of specimen specific for clinical trials
d. Demonstrate knowledge of aseptic technique and universal precautions when dealing with blood
and body products.
e. To aid in the smooth running of the research unit.
f. Demonstrate the ability to follow written and verbal guidelines and instructions essential for
experimental drug trials and clinical research projects
g. Demonstrate proficiency in collection of patient data and the ability to work with understanding and
co-operation within a team of health care workers
h. To actively be involved in research unit meeting
i. Responsibility for operation of trial centre on clinical study days
j. Maintenance of clinical records
k. Maintenance of compliance with study protocol
l. Assisting in the management of the clinical trials centre
m. Preparation of clinic for trial days
n. Taking and recording of clinical observations
o. Collection of blood samples by venipuncture
p. Assist with the planning and implementation of work instructions for use in the clinical setting.
q. Liaise with clinical research associate conducting monitoring activities on behalf of sponsors of
clinical trials
r. Have sound knowledge on ICH/GCP guidelines
޿ࠆ‫ޕ‬Position Purpose ߩᰣߦߪ‫⥃ޟޔ‬ᐥ⹜㛎⎇ⓥߦ
⨶ේ∛㒮ߦ߅ߌࠆ CRC ᬺോߩਛߦߪ Q-Pharm ߢ
㑐ߔࠆ⍮⼂ࠍᜬߜ‫ޔ‬਄ม㧔⹜㛎⽿છකᏧ㧕ࠍ⵬૒ߒ
ߪ SC ߩᬺോߣߪߐࠇߡ޿ߥ޿߽ߩ߇޽ߞߚ‫߃଀ޕ‬
ߡ⾰ߩ㜞޿⥃ᐥ⹜㛎ታᣉߩࡑࡀࠫࡔࡦ࠻ࠍⴕ߁ߎ
߫⨶ේ∛㒮ߩ CRC ߪ‫⹜ޔ‬㛎ଐ㗬⠪ߦࠃࠆᣉ⸳ㆬቯ
ߣ‫ޕࠆ޿ߡࠇࠊ⻭߇ޠ‬
ߩߚ߼ߩ⺞ᩏ⸰໧߳ߩኻᔕ‫ޔ‬IRB ߩߚ߼ߩ⾗ᢱߩᢛ
ᰴߦ‫⨶ޔ‬ේ∛㒮ߦ߅ߌࠆ╩⠪ߩ CRC ߣߒߡߩᬺ
஻‫ޔ‬ᣣ⒟⺞ᢛߣ㐿௅᩺ౝ߿⼏੐㍳૞ᚑߥߤߩ੐ോዪ
ോౝኈࠍ⴫ 3 ߦ␜ߒ‫ޔ‬Q-Pharm ߩ SC ߩ‫ޟ‬Major
ᬺോ‫ࠍࠣࡦ࠾࡯࡝ࠢࠬޔ‬฽߻ⵍ㛎⠪ߩ࡝ࠢ࡞࡯࠻߿
Responsibility Areas‫ߣޠ‬Ყセߒߚ‫⨶ޕ‬ේ∛㒮ߢߪᣣ
⋧⺣ߩኻᔕ‫⮎ޔ‬೷▤ℂ߿⺞೷‫ޔ‬CRA ߦࠃࠆࡕ࠾࠲
Ᏹ⸻≮ߩߚ߼ߩ⚵❱ߣ૕೙ߩਛߢᴦ㛎ᬺോ㧔╙Τ㨪
࡝ࡦࠣ߳ߩኻᔕ‫▤଻ޔ‬ᢥᦠ▤ℂߥߤ߇ᐢߊ቞஻▸࿐
Φ⋧⹜㛎㧕߇ⴕࠊࠇߡ޿ࠆ‫৻ޕ‬ᣇ‫⥃ޔ‬ᐥ⹜㛎ฃ⸤ᯏ
ߣߐࠇߡ޿ࠆ߇‫ޔ‬Q-Pharm ߢߪฦᬺോ߇⚦ಽൻߐࠇ
㑐ߢ޽ࠆ Q-Pharm ߢߪᣣᏱ⸻≮ߪߥߊ‫⥃ޔ‬ᐥ⹜㛎
ߡ߅ࠅߎࠇࠄߩᬺോߪઁㇱ㐷߇ⴕߞߡ޿ߚ‫ޕ‬
㧔ஜᏱੱ෶ߪᖚ⠪ߦࠃࠆ╙ I‫ޔ‬Τ⋧⥃ᐥ⹜㛎‫‛↢ޔ‬
Q-Pharm ߦ߅ߌࠆ SC ߩਥⷐߥᬺോߪ⥃ᐥ⹜㛎㐿ᆎ
ቇ⊛ห╬ᕈ⹜㛎‫‛⮎ޔ‬േᘒ⹜㛎㧕ߦ⋧ᔕߒ޿⚵❱ߣ
ᓟߦ↢ߓࠆࠃ߁ߢ޽ࠆ‫ޔߚ߹ޕ‬Q-Pharm ߢߪ╙Σ⋧
૕೙ࠍᜬߜ‫⹜ޔ‬㛎߇ⴕࠊࠇߡ޿ࠆ‫⊛⋡ߦ߁ࠃߩߎޕ‬
⥃ᐥ⹜㛎߿↢‛ቇ⊛ห╬ᕈ⹜㛎߇߶ߣࠎߤߩߚ߼
߿⚵❱࡮ⅣႺ߇⇣ߥࠆਔᣉ⸳ߦ߅ߌࠆᴦ㛎ታᣉߩታ
ⵍ㛎⠪߆ࠄߩណⴊߪࡌ࠶࠼ࠨࠗ࠼ߢ࡝ࠨ࡯࠴࠽࡯
㓙ࠍᲧセߔࠆߎߣߦߪ⥄ߕߣ㒢⇇ߪ޽ࠆ߇‫⑼ޔ‬ቇᕈ
ࠬ㧔ᣣᧄߢ޿߁⋴⼔Ꮷ㧕߇ⴕߞߡ޿ࠆ‫⨶ޕ‬ේ∛㒮ߢ
߿୶ℂᕈࠍ㊀ⷞߒߟߟวℂൻࠍ࿑ࠆߣ޿߁ὐߢߪ
ߪ╙Τ⋧⥃ᐥ⹜㛎એ㒠ࠍⴕ߁ߚ߼‫ޔ‬ᄖ᧪ߢߩᴦ㛎ߩ
หߓߥߩߢ‫ޔ‬
ᧄ⺰ᢥߢߪᢓ߃ߡਔᣉ⸳ߦ߅ߌࠆ CRC
႐ว CRC ߪᬌᩏㇱ߳ⵍ㛎⠪ࠍ᩺ౝߒ‫⥃ޔ‬ᐥᬌᩏᛛ
㧔SC㧕ߩᬺോౝኈߩᲧセࠍ⹜ߺߚ‫ޕ‬
Ꮷ߇ណⴊࠍߔࠆߩ߇᥉ㅢߢ޽ࠆ‫ޕ‬
5/12
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
43
Kobayashi A et al.
⴫ 3㧦 ⨶ේ∛㒮ߩ CRC ߣ Q-Pharm ߩ SC ߩᬺോ
Events
⹜㛎ߩḰ஻
⨶ේ∛㒮ߩ CRC
z ⹜㛎කᏧ࡮ᴦ㛎ଐ㗬⠪ߦࠃࠆᣉ⸳ㆬቯ⺞ᩏ߳ߩኻᔕ
z ᴦ㛎ଐ㗬⠪ߣߩ㧝ᰴ 2 ᰴࡅࠕ࡝ࡦࠣᵈ 1 ߳ߩᔕኻ‫ޔ‬㒮ౝ
ߩᴦ㛎දജㇱ⟑߳ߩ੐೨ㅪ⛊ߣᴦ㛎ታᣉߦะߌߚ⺞ᢛ
z IRB ↪ክ⼏↳⺧ᦠ㘃ߩ૞ᚑߣ IRB ᆔຬ߳ߩ㈩Ꮣᵈ 2
IRB 㑐ㅪᬺോ
z IRB ߩ੐ോዪᬺോᵈ㧟
Q-Pharm ߩ SC
z ⹜㛎ଐ㗬⠪ߦࠃࠆᣉ⸳⺞ᩏ߿⹜㛎ଐ㗬⠪ߣߩࡅࠕ࡝ࡦ
ࠣኻᔕߪઁㇱ⟑߇ᜂᒰ
z SC ߪ Q-Pharm ౝ߅ࠃ߮⹜㛎ߦදജߔࠆ Brisbane ∛㒮ౝ
ߩઁㇱ⟑ߣߩㅪ⛊࡮⺞ᢛߪⴕࠊߥ޿㧔ઁㇱ⟑߇ᜂᒰ㧕
z Project Manager(PM)߇ IRB ↪ክ⼏↳⺧ߩ૞ᚑߣὐᬌ‫ޕ‬
z Q-Pharm ౝߦ IRB ߪߥ޿ߩߢ SC ߦ੐ോዪᬺോߪ⊒↢ߒ
ߥ޿‫ޕ‬PM ߇㓞ធߔࠆ QMRl ߩ IRB ߳ክ⼏ࠍଐ㗬ߔࠆ
z IRB ክ⼏⚿ᨐㅢ⍮ᦠߩ⊒ⴕ
⹜㛎㐿ᆎḰ஻
⹜㛎㐿ᆎ
⹜㛎ߩታᣉ
z ⵍ㛎⠪ࡈࠔࠗ࡞ߩ૞ᚑᵈ㧠
z ⮎೷▤ℂ⴫ߣ⑌ᱛ࡮೙㒢ߔࠆ૬↪⮎ߩ࡝ࠬ࠻ߩ૞ᚑ
z ᣉ⸳ౝᬌᩏㇱ㐷ߣߩᬌ૕࿁෼࡮ಣℂߣ࠺࡝ࡃ࡝࡯ߥߤߩ
ᛂߜวࠊߖ
z ⹜㛎⽿છකᏧߦࠃࠆࠬ࠲࡯࠻ࠕ࠶ࡊࡒ࡯࠹ࠖࡦࠣߩ㐿
௅ࠍ⵬૒
z ⹜㛎⮎೷ߩฃ㗔‫⮎ޔ‬೷⑼߳ߩ⺑᣿
z ⵍ㛎⠪ࠬࠢ࡝࡯࠾ࡦࠣ㧔ᴦ㛎⽿છකᏧߩᜰ␜ߦࠃࠆ㧕
z ⵍ㛎⠪߳ߩ⺑᣿ߣหᗧขᓧ߳ߩ┙ળ޿‫ޕ‬ขᓧᓟߩᦠ㘃ࠍ
଻▤▤ℂ
z ⹜㛎ታᣉࠬࠤࠫࡘ࡯࡞ߩ▤ℂߣⵍ㛎⠪ߩࠤࠕᵈ 5-1
z CRF ߳ߩ⸥౉㧔කቇ⊛್ᢿߩ઻ࠊߥ޿ㇱಽߩߺ㧕
z ⹜㛎ታᣉߦᔅⷐߣߐࠇࠆෳടઁㇱ㐷ߣߩㅪ⛊⺞ᢛ
z ේ⾗ᢱߩ෼㓸ߣ▤ℂ
z 㧔㊀◊ߥ㧕᦭ኂ੐⽎߳ߩኻᔕᵈ 6
z ᧪㒮ߒߥ޿ⵍ㛎⠪ߩㅊ〔⺞ᩏ‫ޔ‬ᖱႎ෼㓸‫᧪ޔ‬㒮ߩᚻ㈩‫ޔ‬
⸥㍳଻▤
z ⹜㛎ଐ㗬⠪㧔CRA㧕ߦࠃࠆࡕ࠾࠲࡝ࡦࠣ߳ߩኻᔕᵈ 7
z IRB ߳ߩႎ๔ᦠ㘃૞ᚑ㧔⹜㛎⽿છ⠪ࠍ⵬૒㧕ᵈ 8
z ⴊᶧ࡮↢૕ࠨࡦࡊ࡞ណขߩߚ߼ߩⵍ㛎⠪߳ߩࠟࠗ࠳ࡦࠬ
㧔ណⴊ╬ߪઁߩᜂᒰㇱ㐷ߩᬺോ㧕
z CRF ቢᚑߩߚ߼ߩ⹜㛎ଐ㗬⠪(CRA)߳ߩኻᔕ
ᴦ㛎ߩ⚳ੌ
⋙ᩏኻᔕ
z IRB ክ⼏⚿ᨐㅢ⍮ࠍฃ㗔
z ⵍ㛎⠪ࡈࠔࠗ࡞ߩ૞ᚑ
z ⑌ᱛ࡮೙㒢ߔࠆ૬↪⮎࡝ࠬ࠻૞ᚑߩᔅⷐߪߥ޿
z Q-Pharm એᄖߩᬌᩏㇱ㐷ߣߩᬌ૕࿁෼࡮ಣℂߣ࠺࡝ࡃ
࡝࡯ߥߤߩᛂߜวࠊߖ
z ࠬ࠲࡯࠻ࠕ࠶ࡊࡒ࡯࠹ࠖࡦࠣߦ࠴࡯ࡓࡔࡦࡃ࡯ߣߒߡ
ෳട
z ⹜㛎⮎೷ߩฃ㗔࡮଻▤▤ℂߪ⮎೷Ꮷߩᬺോ
z ࠬࠢ࡝࡯࠾ࡦࠣߪ࡝ࠢ࡞࡯࠻࡮ࠝࡈࠖࠨ࡯߇ⴕ߁
z ⹜㛎⽿છකᏧ߇ⵍ㛎⠪ߦ⹜㛎ࠍ⺑᣿ߒหᗧࠍขᓧ
z ⹜㛎ታᣉࠬࠤࠫࡘ࡯࡞ߩ▤ℂߣⵍ㛎⠪ߩࠤࠕᵈ 5-2
z CRF ߳ߩ⸥౉ߣౝኈ⏕⹺
z ⹜㛎ታᣉߩࡑࡀࠫࡔࡦ࠻㧔⹜㛎⽿છ⠪ࠍ⵬૒㧕
z ේ⾗ᢱߩ଻▤▤ℂߪઁㇱ⟑߇ᜂᒰ
z ᦭ኂ෻ᔕ߳ߩኻᔕߣ⸥㍳ᵈ 6
z ᧪㒮ߒߥ޿ⵍ㛎⠪ߩㅊ〔⺞ᩏ‫ޔ‬ᖱႎ෼㓸‫᧪ޔ‬㒮ߩᚻ㈩‫ޔ‬
⸥㍳଻▤
z ࡕ࠾࠲࡝ࡦࠣ߳ߩኻᔕᵈ 7
z IRB ߳ߩႎ๔ᦠ㘃૞ᚑ㧔⹜㛎⽿છ⠪ࠍ⵬૒㧕ᵈ 8
z ⴊᶧ࡮↢૕ࠨࡦࡊ࡞ߩណข
z PM ߇ CRF ቢᚑߩߚ߼ߩ⹜㛎ଐ㗬⠪(CRA)߳ߩኻᔕ‫ޔ‬
CRC ߪ PM ࠍ⵬૒
z ઁㇱ⟑㧔Archive㧕߇ᔅ㗇ᢥᦠ߅ࠃ߮ߔߴߡߩᴦ㛎㑐ㅪᢥ
ᦠࠍ଻▤▤ℂ
z ᔅ㗇ᢥᦠ߅ࠃ߮ߔߴߡߩ⹜㛎㑐ㅪ⸥㍳ᢥᦠߩ଻▤▤ℂ
z ᣉ⸳߇଻▤▤ℂߔࠆએᄖߩᴦ㛎㑐ㅪᢥᦠ‫⹜ޔ‬㛎⮎೷ઁߩ
ࡑ࠹࡝ࠕ࡞ࠍᴦ㛎ଐ㗬⠪߳㄰ළ
z ᣉ⸳߇଻▤▤ℂߔࠆએᄖߩ⹜㛎㑐ㅪᢥᦠ‫⹜ޔ‬㛎⮎೷ઁߩ
z ⹜㛎⽿છකᏧ߇⹜㛎✚᜝ႎ๔ᦠࠍ૞ᚑ‫ޔ‬SC ߪ૞ᚑࠍ⵬
ࡑ࠹࡝ࠕ࡞ߩὐᬌ‫⹜ޔ‬㛎ଐ㗬⠪߳㄰ළ
૒
z ઁᣉ⸳⥃ᐥ⹜㛎߇ᄙߊ‫⹜ޔ‬㛎✚᜝ႎ๔ᦠߪ૞ᚑߒߥ޿‫ޕ‬
z ߘߩઁߩႎ๔ᦠ㘃ߩ૞ᚑߣ IRB ߳ߩឭ಴㧔⹜㛎⽿છක z ႎ๔ᦠ㘃ߩ૞ᚑߣ IRB ߳ߩឭ಴㧔⹜㛎⽿છකᏧ߳ߩ⵬૒
ߣߒߡ㧕
Ꮷ߳ߩ⵬૒ߣߒߡ㧕
z ⋙ᩏ࡮ᩏኤ╬ᵈ 9-1 ߳ߩኻᔕ
z QAU ߇⋙ᩏ࡮ᩏኤ╬ᵈ 9-2 ߳ߩኻᔕ‫ޔ‬SC ߪ QAU ࠍ⵬૒
ᵈ 1㧦㧝ᰴࡅࠕ࡝ࡦࠣߢߪ⹜㛎ଐ㗬⠪߇ CRC ߳ߩᴦ㛎ౝኈࠍ⺑᣿‫⺑ޕ‬᣿ࠍฃߌߚ CRC ߪ⹜㛎ߦ㑐ㅪߔࠆㇱ⟑㧔⋴⼔ㇱ‫⮎ޔ‬೷⑼‫ޔ‬ᬌᩏ⑼‫ޔ‬᡼኿✢⑼‫ޔ⑼࡝ࡆࡂ࡝ޔ‬ක≮ㅪ៤ㇱ‫ޔ‬
ක੐⑼‫ޔ‬ᐼോ⺖ߥߤ㧕ߦ⹜㛎ߩ᭎⇛ࠍ⺑᣿ߒ‫ޔ‬ታᣉߩน⢻ᕈࠍᛠីߔࠆ‫ޕ‬㧞ᰴࡅࠕ࡝ࡦࠣߢߪ⹜㛎ଐ㗬⠪߇කᏧ‫⼔⋴ޔ‬Ꮷ‫⮎ޔ‬೷Ꮷ‫⥃ޔ‬ᐥᬌᩏᛛᏧ‫ޔ‬ᐼോ⺖߳ߩ⹜㛎ౝኈࠍ
⺑᣿‫ޕ‬
ᵈ 2㧦↳⺧ᦠ㘃ߩ࠴ࠚ࠶ࠢ‫▚࠻ࠬࠦޔ‬಴‫⺑ޔ‬᣿ᢥᦠߣหᗧᦠ૞ᚑදജ‫ޔ‬කᏧߩጁᱧᦠ࡮ᴦ㛎දജ⠪ߩ࡝ࠬ࠻૞ᚑ‫ޔ‬ᐢ๔߿ෳടࠞ࡯࠼૞ᚑߥߤ
ᵈ㧟㧦ᴦ㛎⽿છ⠪߳ߩ㐿௅ㅢ⍮‫ޔ‬ክ⼏↳⺧ᦠ㘃ߩ㈩Ꮣ‫⼏ޔ‬੐㍳ߩ૞ᚑߥߤ㧕
ᵈ㧠㧦ฦᬌᩏߩ⺧᳞વ␿߿ಣᣇ▐ߥߤࠬࠤࠫࡘ࡯࡞ߦᴪߞߚ࠮࠶࠻ߩ↪ᗧ㧕
ᵈ 5-1㧦ⵍ㛎⠪ߩ૕⺞⏕⹺‫┙ߩ߳≮⸻ޔ‬ળ޿‫ߦ࡞࡯ࡘࠫࠤࠬޔ‬ᴪߞߚⷰኤ࡮ᬌᩏߩ⺑᣿ߣᬌᩏቶ߳ߩࠟࠗ࠼‫ޔ‬ᰴ࿁ฃ⸻ࠬࠤࠫࡘ࡯࡞ߩ⺞ᢛ࡮▤ℂߥߤ‫ޕ‬
ᵈ 5-2㧦ⵍ㛎⠪ߩ૕⺞⏕⹺‫┙ߩ߳≮⸻ޔ‬ળ޿‫ߦ࡞࡯ࡘࠫࠤࠬޔ‬ᴪߞߚⷰኤ࡮ᬌᩏ࡮ណⴊ࡮↢૕ࠨࡦࡊ࡞ߩណข‫ޔ‬ᰴ࿁ฃ⸻ࠬࠤࠫࡘ࡯࡞ߩ⺞ᢛ࡮▤ℂ‫ᤨ⥃ޔ‬⡯ຬ߳ߩᜰ␜ߥߤ
ᵈ 6㧦ⵍ㛎⠪ኻᔕ‫ޔ‬කᏧ߳ߩㅪ⛊‫ޔ‬ᖱႎ෼㓸‫ޔ‬ᴦ㛎ଐ㗬⠪߳ߩႎ๔ߩ⵬૒‫ޔ‬㒮ౝ߳ߩㅪ⛊‫⸥ޔ‬㍳ߣߘߩ଻▤ߥߤ
ᵈ 7㧦ࡕ࠾࠲࡝ࡦࠣࠬࠤࠫࡘ࡯࡞ߩ▤ℂ‫ޔ‬ේ⾗ᢱߩ↪ᗧ‫ߩ߳࡯࡝ࠛࠢޔ‬ኻᔕ‫ޔ‬ᴦ㛎⽿છ㧔ಽᜂ㧕කᏧ߳ߩㅪ⛊
ᵈ 8㧦቟ోᕈᖱႎ‫⛯⛮ޔ‬ክ⼏‫ޔ‬ᴦ㛎ታᣉ⸘↹ᦠߩ৻ㇱᄌᦝ‫ޔ‬ᴦ㛎ಽᜂකᏧߩㅊടߣ೥㒰‫ࠣࡦ࡝࠲࠾ࡕޔ‬ႎ๔‫ߩઁߩߘޔ‬シᓸߥ੐㗄ߥߤ
ᵈ 9-1㧦⹜㛎ଐ㗬⠪‫ޔ‬㒮ౝߩ⋙ᩏㇱ㐷‫ⷙޔ‬೙ᒰዪߦࠃࠆ⋙ᩏ࡮ᩏኤ߳ߩኻᔕ
3. ⹜㛎⽿છකᏧߣࠦ࡯࠺ࠖࡀ࡯࠲࡯ߣߩ㑐ଥ
⽿છකᏧࠍൕ߼ߡ߅ࠅ Q-Pharm ߦߪᏱൕߒߡ޿ߥ
Q-Pharm ߩ⹜㛎⽿છකᏧߪᣣᧄߩ⹜㛎⽿છ㧔ಽ
޿‫⹜ޕ‬㛎ታᣉᒰᣣ㧔ᄢ૕ㅳ 3 ᣣ㧕ߩᦺ Q-Pharm ߦ
ᜂ㧕කᏧߦᲧߴߡ⹜㛎ታᣉ⸘↹ᦠ㧔ࡊࡠ࠻ࠦ࡯࡞㧕
಴ൕߒ‫ޔ‬1 ᣣਛᣉ⸳ౝߢ⹜㛎ߦ៤ࠊߞߡ޿ࠆ‫╩ޕ‬⠪
߳ߩℂ⸃ᐲ߇ᷓߊ‫ޔ‬ᴦ㛎ߩਛᔃੱ‛ߣߒߡߩሽ࿷ᗵ
߇⎇ୃߒߡ޿ߚ 3 ࡨ᦬ߩ㑆ߦ 18 ߩࡊࡠ࠻ࠦ࡯࡞
㧔╙
߇㜞޿‫ޕ‬Q-Pharm ߢߪࡄ࡯࠻࠲ࠗࡓකᏧ 4 ฬ߇⹜㛎
Σ⋧⥃ᐥ⹜㛎ߣ BE ⹜㛎㧕ߩ⹜㛎߇ㅴ߼ࠄࠇߡ޿ߚ
44
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
6/12
原著論文
߇‫ߩߘޔ‬ᄙߊࠍ৻ੱߩᅚᕈකᏧ߇⹜㛎⽿છකᏧࠍോ
߆ࠄߢ޽ࠆ‫ࠊ߆޿ߥ߈ߢ߇ࠢ࠶ࠚ࠴࡞ࡉ࠳ߒ߆ߒޕ‬
߼ߡ޿ߚ‫ޕ‬Q-Pharm ߢߪⵍ㛎⠪ߦኻߔࠆ⹜㛎ߩ⺑᣿
ࠅߦ‫⮎ߦ߁ࠃ޿ߥ߈⿠߇ࠬࡒޔ‬೷࠴ࡘ࡯ࡉߦࠪ࡯࡞
ߣหᗧขᓧߪߎߩකᏧߣⵍ㛎⠪ߩ㑆ߢⴕࠊࠇߡ߅
ࠍߪࠅ૗ᐲ߽࠴ࠚ࠶ࠢࠍߒߚࠅ࠴ࡘ࡯ࡉࠍ⦡ಽߌ
ࠅ‫ޔ‬SC ߪ․ߦ㑐ਈߒߡ޿ߥ޿‫⨶ޕ‬ේ∛㒮ߢߪ⹜㛎
ߒߚࠅ‫ࠢ࠶ࠚ࠴ޔ‬ᣇᑼߩ࡝ࠬ࠻ࠍ૶ߞߚࠅߣࡒࠬ㒐
⽿છ㧔ಽᜂ㧕කᏧ߇ⵍ㛎⠪ߦ⹜㛎ߩ᭎⇛ࠍ⺑᣿ࠍߒ
ᱛ╷߇ᚲ‫⷗ߢޘ‬ฃߌࠄࠇ‫ޔ‬1 ੱ⮎೷Ꮷ૕೙ߢ߽චಽ
ߚᓟ‫ޔ‬ㅢᏱ CRC ߇⵬⿷⺑᣿ࠍߔࠆߩߢ╩⠪ߦߣߞ
ࡒࠬߥߊ⺞೷ࠍߒߡ޿ࠆᆫ߇ශ⽎⊛ߢ޽ߞߚ㧔੹߹
ߡߎࠇߪએᄖߢ޽ߞߚ‫޿⸒ޕ‬឵߃ࠇ߫‫ޔ‬Q-Pharm ߩ
ߢ 1 ᐲ߽ࡒࠬߪߥ޿ߣߎߣߢ޽ߞߚ㧕‫޿ߡߒ↪૶ޕ‬
කᏧߪ⥄ಽߩ∛㒮ߢߩ⸻≮ᬺോߣ Q-Pharm ߢߩᴦ
ࠆ⮎೷▤ℂ⴫߽ಣᣇ▐߽ᒻᑼ߇᳿߹ߞߡ޿ࠆ߽ߩ
㛎ᬺോ෺ᣇࠍᛴ߃ߡ޿ࠆ߽ߩߩ‫ࠍࠄࠇߎޔ‬หᤨਗⴕ
ߢߥ޿ߚ߼⥄ಽ߇૶޿߿ߔ޿ࠃ߁ߦ૞ᚑߒ‫⹜ޔ‬㛎⽿
⊛ߦߎߥߔߩߢߪߥߊ‫ޔ‬ᣣᲤߦ᣿⏕ߦಽߌߡߘࠇߙ
છකᏧߩࠨࠗࡦࠍ߽ࠄ߃߫ේ⾗ᢱߣߒߡ⹺߼ࠄࠇ
ࠇߦᓥ੐ߒߡ޿ࠆ‫ޕ‬
ࠆߣ޿߁ࠪࠬ࠹ࡓߥߩߢᴦ㛎Ḱ஻ߪ޿ߟ߽ᚻᣧ
⹜㛎ߪㅢᏱᦺ 6 ᤨ೨߆ࠄࠬ࠲࡯࠻ߒߡ޿ߚ‫⹜ޕ‬㛎
߆ߞߚ‫ޕ‬ᴦ㛎⮎⺞೷ᓟߩᱷ⮎‫ޔ‬ⓨࠪ࡯࠻㄰ළߪᣣᧄ
ታᣉਛߪ૗ᐲߣߥߊ SC ߇⹜㛎ቶਛᄩߩࡉ࡯ࠬߦ⹜
ߩࠃ߁ߦ෩ߒߊߥߊ‫ޔ‬૗㧑᦯↪ߩ⸥㍳ߩߺߢ 1 ㍤න
㛎࠴࡯ࡓࡔࡦࡃ࡯ࠍถ㓸ߒ‫ޔ‬ฦಽᜂᬺോࠍ⏕⹺ߒ‫ޔ‬
૏ߢߩ⸥㍳ߪขߞߡ޿ߥ߆ߞߚ‫ߥߪߢߡో߽߆ߒޕ‬
ᜰ␜ࠍ಴ߔߥߤ‫⹜ޔ‬㛎ߩࠬࡓ࡯࠭ߥㅴⴕߩߚ߼ߦ߆
޿߇ࡊࡠ࠻ࠦ࡯࡞ߦࠃߞߡߪ⮎೷Ꮷ߇⸥㍳ࠍᱷߖ
ߥࠅߩ᳇㈩ࠅࠍߒߡ޿ߚ‫ ࠼࠶ࡌߪߦᤨޕ‬1 ߟ 1 ߟࠍ
߫ⵍ㛎⠪߆ࠄߩ㄰ළ⮎ߪ⎕᫈ߢ߈ࠆ߽ߩ߽޽ࠅᄢ
๟ࠅࠬ࠲࠶ࡈ߿ⵍ㛎⠪ߦჿࠍ߆ߌߟߟ㧔ߎߩᤨ‫∝ޔ‬
ᄌᗧᄖߢ޽ߞߚ‫ޕ‬Q-Pharm ߢߪ 1 ࡨ᦬ߦ 1 ࿁ฦࡈࡠ
଀ႎ๔ᦠߦᔅⷐߥᖱႎࠍࠗࡦ࠲ࡆࡘ࡯ߒߡ޿ࠆ㧕‫ޔ‬
ࠕߦ⸳⟎ߐࠇߡ޿ࠆ✕ᕆࠞ࡯࠻ߩὐᬌࠍߒߡ޿ࠆ‫ޕ‬
ో૕ߩㅴⴕࠍ▤ℂ⛔᜝ߒߡ޿ߚ‫ߦ⊛⚳ᦨߒ߆ߒޕ‬ක
ṛ࿷ᦼ㑆ਛ╩⠪ߪὐᬌߦᔅߕหⴕߐߖߡ߽ࠄ޿‫᦭ޔ‬
Ꮷ߇್ᢿߔߴ߈ߣߎࠈߢߪᔅߕ⹜㛎⽿છකᏧ߇ⷐ
ኂ੐⽎⊒↢ߦ஻߃ߚ⮎೷▤ℂ߽૕㛎ߢ߈ߚ‫ࠬࠖ࠺ޕ‬
ᚲߦᜰ␜ࠍ಴ߒ‫ߦ࠭࡯ࡓࠬޔ‬ᴦ㛎ߩࠬࠤࠫࡘ࡯࡞߇
ࡐ࠲ࠗࡊߩ㎛ࠍ૶↪ߒ⮎೷ߩ⋑㔍߿ੂ↪߇ߥ޿ࠃ
ታⴕߐࠇߡ޿ߚ‫ޕ‬
߁ߦ㎛ߦ․᦭ߩ࠽ࡦࡃ࡯߇߰ߞߡ޽ࠅ‫߇⺕ޔ‬㐿ߌ㐽
⨶ේ∛㒮ߢ CRC ࠍൕ߼ߡ޿ࠆ╩⠪ߦߪ‫⹜ޔ‬㛎
߼ࠍߒߚ߆߽⸥㍳ߔࠆࠃ߁▤ℂ߇߈ߜࠎߣߥߐࠇ
࠴࡯ࡓࡔࡦࡃ࡯߇ᣉ⸳ౝߩห৻ࡈࡠࠕߢ৻૕ߣߥ
ߡ޿ߚ‫ߒ߆ߒޕ‬ᐘ޿੹߹ߢෂ㒾ࠍ᜗ߊ੐⽎߇߶ߣࠎ
ࠅㅪ៤ߒߡ‫ޔ‬ᄙߊߩⵍ㛎⠪ߦࠃࠆ⹜㛎ࠍല₸⊛ߦㅴ
ߤߥ߆ߞߚߎߣ‫ޔ‬Q-Pharm ߪ RBH ∛㒮⟲ౝߦ޽ࠅ
߼ߡ޿ࠆ⁁ᴫߦធߒߚߩߪೋ߼ߡߢ޽ߞߚߩߢᭂ
ਁ߇৻㊀◊ߥ᦭ኂ੐⽎߇⿠߈ߚᤨߦߪ∛㒮߆ࠄ࡟
߼ߡශ⽎⊛ߢ޽ߞߚ‫⹜ߥ߁ࠃߩߎޕ‬㛎ታᣉߢߪߘߩ
ࠬࠠࡘ࡯࠴࡯ࡓ߇߿ߞߡ᧪ߡㄦㅦߥಣ⟎ࠍߔࠆ૕
႐ߩ⁁ᴫߦᔕߓߚ್ᢿߦၮߠ޿ߚᜰ␜߇น⢻ߢ޽
೙ߦߥߞߡ޿ࠆߎߣߦࠃࠅ✕ᕆࠞ࡯࠻ౝߩ⮎೷ߪ
ࠅ‫੍ޔ‬᷹ࠍ⿥߃ߚ⓭ὼߩ੐ᘒߦኻߔࠆහᐳߩℂ⸃‫ޔ‬
૶↪ߐࠇߕᦼ㒢ಾࠇߦߥࠆ߽ߩ߇ᄙ޿ߣߩߎߣߢ
ㄦㅦߥ್ᢿߣⴕേ߇น⢻ߢ޽ࠈ߁‫ߚߒ߁ߎޕ‬ኻᔕߪ
޽ߞߚ‫ޕ‬
ߤߩᲑ㓏ߩᴦ㛎ߢ߽࿑ࠆߎߣ߇ᔅⷐߢ޽ࠆߣᕁࠊ
ࠇࠆ‫ޕ‬
⠨ኤ
4. ⮎೷Ꮷߩᬺോ
⨶ේ∛㒮ߩ⮎೷ㇱ߇ᴦ㛎⮎೷ࠍขᛒ߁ߩߣߪ⇣
ࠊ߇࿖ߢ‫ޟ‬ක⮎ຠߩ⥃ᐥ⹜㛎ߩታᣉၮḰ‫߇ޠ‬ᴺ೙
ߥࠅ‫ޔ‬Q-Pharm ߢߪᣣᏱ⸻≮ߪߥ޿ߚ߼ᴦ㛎⮎೷ߛ
ൻߐࠇߡ߆ࠄᣢߦ 10 ᐕ߇⚻ㆊߒߚ‫ޕ‬ICH-GCP ߩዉ
ߌࠍᛒߞߡ޿ࠆ‫ޕ‬1 ੱߩ⮎೷Ꮷ߇ోߡߩᴦ㛎⮎ߩ⺞
౉એ㒠‫ޔ‬਎⇇⊛ߦߪᴦ㛎ߩࠣࡠ࡯ࡃ࡞ൻߣฦ࿖ߢߩ
೷ߣ▤ℂߩᬺോࠍછߐࠇߡ޿ࠆ‫ޕ‬㧝ੱ⮎೷Ꮷ૕೙ߩ
⹜㛎࠺࡯࠲ߩᣂ⮎⸵นᛚ⹺ߩߚ߼ߩ౒↪ൻߩ௑ะ
ߚ߼⺞೷ߩ࠳ࡉ࡞࠴ࠚ࠶ࠢߪߢ߈ߥ޿ߩߢೋ߼╩
߇߹ߔ߹ߔჇടߒߡ޿ࠆ‫ޔߡߒߘޕ‬ㄭᐕߢߪ᰷☨⻉
⠪ߪ㆑๺ᗵࠍⷡ߃ߚ‫⨶ޕ‬ේ∛㒮ߩ⮎೷ㇱߢߪᴦ㛎⮎
࿖࡮ධࠕࡔ࡝ࠞ࡮᧲᰷⻉࿖߫߆ࠅߢߥߊ‫᧲ޔ‬ධࠕࠫ
⺞೷ߢߪ૗ੱ߽ߩ࠴ࠚ࠶ࠢ߇౉ࠅ⺞೷ࠍߒߡ޿ࠆ
ࠕ⻉࿖߽ࠣࡠ࡯ࡃ࡞ᴦ㛎ߦෳ↹ߒᆎ߼ߡ޿ࠆ‫৻ޕ‬ᣇ‫ޔ‬
7/12
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
45
Kobayashi A et al.
ࠊ߇࿖ߪߥ߆ߥ߆ࠣࡠ࡯ࡃ࡞ᴦ㛎ߩખ㑆౉ࠅ߇ߢ
ࠨ࡯࠴㧕ߢ޽ࠆ‫ޕ‬㐿⊒Ბ㓏ߢഃࠄࠇߚฦ⒳ߩᖱႎ߇
߈ߦߊ޿ߩ߇⃻⁁ߢ޽ࠆ‫ߡߒߘޕ‬ᶏᄖߩ⵾⮎ડᬺߩ
ᭂ߼ߡ⍴ߊⷐ⚂ߐࠇ‫ޔ‬ឝタߐࠇߡ޿ࠆߩ߇ක⮎ຠߩ
ᄙߊߪ⃻࿷ߢߪᣣᧄࠍ㒰޿ߚ⻉࿖ߢᴦ㛎ࠍታᣉߒ
ᷝઃᢥᦠߢ޽ࠅ‫ߪߦߎߘޔ‬ㆡᱜ૶↪ߩߚ߼ߩၮᧄ⊛
ߡ޿ࠆ‫ޔߚ߹ޕ‬ᣣᧄߩᄢᚻ⵾⮎ડᬺ߽ᶏᄖఝవߢᴦ
ᜰ㊎߇␜ߐࠇߡ޿ࠆ‫⮎ޕ‬೷Ꮷࠍ฽߻⮎ቇᛛⴚ⠪߇න
㛎ࠍㅴ߼ࠆ௑ะ߇Ⴧ߃ߟߟ޽ࠆ‫ߚߒ߁ߎޕ‬ᣣᧄ߆ࠄ
ߦᷝઃᢥᦠ਄ߩ⸥タߩℂ⸃ߩߺߦ⇐߹ࠄߕ‫⸥ޔ‬タᖱ
ߩᴦ㛎㔌ࠇ‫ޔ‬ᴦ㛎ߩⓨᵢൻ߇ㅴ߻ߎߣߪ‫ߪߡ޿߭ޔ‬
ႎ߇ߤߩࠃ߁ߥ߆ߚߜߢ‫ߦ߁ࠃߩߤޔ‬ഃ಴ߐࠇࠆ߆
ᣣᧄߩᖚ⠪߇਎⇇ᦨవ┵ߩ⮎‛ᴦ≮ࠍฃߌࠄࠇߥ
ࠍℂ⸃ߒߡ߅ߊߎߣߪ‫ޔ‬ᓐࠄߩᵢኤജߩᩰᲑߩะ਄
޿ߎߣߦ❬߇ࠅ߆ߨߥ޿‫ޕ‬ෘ↢ഭ௛⋭߅ࠃ߮ᢥㇱ⑼
ࠍଦߒ‫ޔ‬ⓥᭂ⊛ߦߪ⾰ߩ㜞޿ක≮ߩଏ⛎ߦ❬߇ࠆߣ
ቇ⋭ߪߎߩኻ╷ߣߒߡᐔᚑ 15 ᐕߦ
‫ޟ‬ᴦ㛎ᵴᕈൻ 3 ࡨ
⠨߃ࠄࠇࠆ‫੹ޕ‬ᓟ␠ળ߆ࠄ㜞޿⹏ଔࠍฃߌ‫࡯ࡠࠣޔ‬
ᐕ⸘↹‫ޔߡ┙ࠍޠ‬ᣣᧄߩᴦ㛎ⅣႺߩᢛ஻ࠍ࿑ߞߡ߈
ࡃ࡞ᴦ㛎߽ⴕ޿ᓧࠆੱ᧚ߩ⢒ᚑߩߚ߼ߦ‫♽⮎ޔ‬ᄢቇ
ߚ‫ޔߚ߹ޕ‬ᐔᚑ 19 ᐕ 4 ᦬߆ࠄߪᦝߦ‫ޟ‬ᣂߒ޿ᴦ㛎
ߦ߅ߌࠆ⥃ᐥ⹏ଔ㑐ㅪߩ⎇ⓥ࡮ᢎ⢒ᵴേߩ㊀ⷐᕈߪ
ᵴᕈൻ 5 ࡨᐕ⸘↹‫ࠍޠ‬ឭ᩺ߒ‫ޔ‬ᣣᧄߦ߅ߌࠆක⮎ຠ
৻ጀ㜞߹ࠆߣᕁࠊࠇࠆ‫ޕ‬
એ਄ߩ⠨߃ߦ┙ߜ౒┙⮎⑼ᄢቇߪᐔᚑ 16 ᐕ㧠᦬‫ޔ‬
ߩ⥃ᐥ⹏ଔᵴേߩല₸ൻߣ࿖㓙⊛⺞๺ߦ߻ߌߚฦ
ઁᄢቇߦవ㚟ߌߡ‫⥃ޟ‬ᐥ⮎‛⹏ଔቇ⻠ᐳ‫ࠍޠ‬ഃ⸳ߒ
⒳ߩᣉ╷ࠍ⻠ߓߟߟ޽ࠆ‫ޕ‬
ක⮎ຠߪᧄ⾰⊛ߦߪੱ⒳߿࿾ၞᕈࠍ઻ࠊߥ޿ੱ
ߚ‫ޕ‬ᒁ߈⛯߈‫ޔ‬࿖㓙⊛ⷞ㊁߆ࠄ⥃ᐥ⮎‛⹏ଔߩቇⴚ
㘃౒ㅢߩ⽷↥ߢ޽ࠆߩߢ‫ߥ߁ࠃߩߎޔ‬ක⮎ຠ㐿⊒ߩ
⎇ⓥߣੱ᧚⢒ᚑࠍ࿑ࠆ⋡⊛ߢᐔᚑ 17 ᐕ 6 ᦬ࠝ࡯ࠬ
ࠣࡠ࡯ࡃ࡞ൻ߿⥃ᐥㆡ↪ߩ౒ㅢൻߪ․ቯߩⷐ࿃ߦ
࠻࡜࡝ࠕߩࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᄢቇߣቇⴚឭ៤ᄾ⚂
ၮߠߊ߽ߩߢߥߌࠇ߫ᤚ⹺ߐࠇߡὼࠆߴ߈߽ߩߢ
ࠍ✦⚿ߒߚ‫ޕ‬
․ߦࠝ࡯ࠬ࠻࡜࡝ࠕߦ⌕⋡ߒߚߩߪᰴߩℂ↱ߦ
޽ࠅ‫ߩߎޔ‬௑ะߪ੹ᓟ߽৻ጀㅴ߻ߣ⠨߃ࠄࠇࠆ‫ޕ‬ᴦ
㛎ߩⓨᵢൻࠍ㒐߉‫ޔ‬ᴦ㛎ߩࠣࡠ࡯ࡃ࡞ൻߩᵹࠇߦਸ਼
ࠃࠆ‫ޕ‬
ࠆߎߣߪᣣᧄߩක≮ߦߣߞߡߪᄢ߈ߥ⺖㗴ߢ޽ࠆ
1㧕ࠝ࡯ࠬ࠻࡜࡝ࠕߩකቇ࡮ࡃࠗࠝࠨࠗࠛࡦࠬߩ࡟
ࡌ࡞ߪ㜞޿ߎߣ‫ޕ‬
߇‫ࠍࠇߎޔ‬น⢻ߦߔࠆߚ߼ߦߪ‫ޔ‬ᣣᧄએᄖߩᴦ㛎Ⅳ
Ⴚ߿ක≮ᢥൻࠍℂ⸃ߒߡᣣᧄߩක≮ߣߩ⺞๺ࠍ
ഃ⮎⎇ⓥߢߪߎࠇ߹ߢߦᐞߟ߽ߩᚑᨐࠍ᜼ߍ
࿑ߞߚࠅ‫࡞ࡃ࡯ࡠࠣޔ‬ᴦ㛎ࠍផㅴߢ߈ࠆੱ᧚ࠍᣣᧄ
ߡ߈ߡ޿ࠆ‫ޕ‬ば∛ᴦ≮⮎ߣߒߡߩ࡝࠴࠙ࡓߩ⊒⷗‫ޔ‬
ߢ⢒ᚑߔࠆߎߣ߇ᔅⷐߢ޽ࠆ‫ޕ‬
ࠗࡦࡈ࡞ࠛࡦࠩᗵᨴᴦ≮ߩߚ߼ߩࡁࠗ࡜ࡒ࠾
‫ޟ‬ක⮎ຠ㐿⊒‫ߪߣޠ‬ၮ␆⎇ⓥ߆ࠄ↢߹ࠇࠆᣂⷙ↢
࠳ ࡯ ࠯ 㒖 ኂ ⮎ ߩ ഃ ⮎ ⎇ ⓥ ‫ ޔ‬B.J.Marshall ߣ
‛ᵴᕈ‛⾰ߩක≮߳ߩᔕ↪․ᕈࠍ⷗ᭂ߼‫ޔ‬ක⮎ຠߩ
J.R.Warren ਔඳ჻ߦࠃࠆࡋ࡝ࠦࡃࠢ࠲࡯࡮ࡇࡠ࡝
ㆡᱜ૶↪ߩߚ߼ߩᖱႎࠍഃ಴ߔࠆߎߣߢ޽ࠆ‫ޕ‬หᤨ
ߩ⊒⷗ߣᶖൻᕈẩ≌ߦኻߔࠆᣂߚߥᴦ≮ᴺߩ㐿
ߦ‫ޔ‬ක⮎ຠߣߒߡߩຠ⾰⏕଻ߣ቟ቯଏ⛎߇น⢻ߥᛛ
⊒ߥߤߪߘߩ৻଀ߢ޽ࠆ‫ޕ‬
ⴚࠍ㐿⊒ߔࠆߎߣߢ߽޽ࠆ‫ޕ‬
2㧕ࠝ࡯ࠬ࠻࡜࡝ࠕߪ࿖㓙ᴦ㛎ߩ⚻㛎߇⼾ንߢ޽ࠆ
ක⮎ຠߩ⎇ⓥ㐿⊒ࡊࡠ࠮ࠬߩਛߢᴦ㛎ߪක⮎ຠ
ㆡᱜ૶↪ߦᔅⷐߥᖱႎࠍഃ಴ߔࠆࠬ࠹࠶ࡊߢ޽ࠅ‫ޔ‬
ߎߣ‫ޕ‬
ࠝ࡯ࠬ࠻࡜࡝ࠕߩකቇ࡮ක≮ᢥൻߪ⧷࿖ߩᒝ޿
ᣂ⮎㐿⊒ᵴേߩਛᩭߣ૏⟎ߠߌࠄࠇࠆ‫ޕ‬ᣣᧄߩ⮎♽
ᓇ㗀ࠍฃߌߡ߅ࠅ‫⥃ޔ‬ᐥ⎇ⓥߩ⑼ቇᕈߣ୶ℂᕈߦ
ᄢቇߢߪഃ⸳એ᧪‫⮎ޔ‬೷Ꮷ㙃ᚑߦട߃ߡᣂ⮎ߩ⎇ⓥ
㑐ߒߡߪ ICH ߩᕁᗐߣታ〣ࠍขࠅ౉ࠇߡ޿ࠆ‫ޕ‬ᣂ
㐿⊒ߦ㑐ࠊࠆቇⴚ⎇ⓥࠍዷ㐿ߒߡ߈ߚ‫ߪࠇߎޕ‬਎⇇
⮎㐿⊒߇น⢻ߥⷙᮨߩ⵾⮎ડᬺߪߥ޿߽ߩߩ‫ޔ‬
ߦߪ㘃ࠍ⷗ߥ޿․⦡ߢ޽ࠆ‫‛⮎ޔࠄ߇ߥ޿⸒ߪߣޕ‬
ࠝ࡯ࠬ࠻࡜࡝ࠕߪߎࠇ߹ߢߦ߽࿖㓙ᴦ㛎ߦⓍᭂ
ߩ⥃ᐥ⹏ଔߦ㑐ࠊࠆ⎇ⓥ߿ᢎ⢒ᵴേ߇⋓ࠎߦㅴ߼
⊛ߦෳടߒߡ߈ߡ޿ࠆ‫☨ޕ‬࿖ NIH ߦ⊓㍳ߐࠇߡ
ࠄࠇߡ߈ߚߣߪ⸒޿߇ߚ޿ߩ߽⃻⁁ߢ޽ࠆ‫ޕ‬
޿ࠆ࿖㓙⊛⥃ᐥ⹜㛎ᢙߢߺࠆߣࠝ࡯ࠬ࠻࡜࡝ࠕ
ᴦ㛎ࠍ฽߻⮎‛ߩ⥃ᐥ⹏ଔߪ⥄ὼ⑼ቇߣੱᢥ࡮⚻
ߪ 87 ࠞ࿖ਛ 10 ⇟⋡ߦ࡜ࡦࠢߐࠇߡ޿ࠆ‫ޕ‬࿃ߺߦ‫ޔ‬
ᷣ࡮୶ℂߩࠃ߁ߥ␠ળ⑼ቇߣߩ⛔วߩ਄ߦᚑࠅ┙ߟ
ᣣᧄߪ╙ 60 ૏ߢ޽ࠅ㖧࿖‫ޔ‬บḧ‫ޔࠕࠪ࡯࡟ࡑޔ‬
ᅏߩᷓ޿ቇⴚ⎇ⓥᵴേ㧔ࡅࡘ࡯ࡑࡦࠨࠗࠛࡦࠬ࡝
㚅᷼‫ޔ‬ਛ࿖‫߽ࠅࠃࠕࠪࡀ࠼ࡦࠗޔ‬ਅ૏ߦ޽ࠆ 2㧕‫ޕ‬
46
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
8/12
原著論文
ᴫߣ޿߁ශ⽎߇޽ࠆ‫ޕ‬
3㧕ࠝ࡯ࠬ࠻࡜࡝ࠕߪ⧷⺆ࠍᲣ࿖⺆ߣߒ‫᧲߽߆ߒޔ‬
2㧕Q-Pharm ߩ SC ߩᬺോߩ▸࿐ߪਥߣߒߡ⥃ᐥ⹜
ධࠕࠫࠕߩ৻ⷺߦ૏⟎ߒߡ޿ࠆߎߣ‫ޕ‬
㛎㐿ᆎએᓟߦ㒢ቯߐࠇߡ޿ࠆߩߦኻߒ‫⨶ޔ‬ේ∛
ࠝ࡯ࠬ࠻࡜࡝ࠕߪ⧷⺆࿤ߩ৻࿖ߢ޽ࠅߥ߇ࠄ
ࠕࠫࠕ⻉࿖ߩㄭ㓞ߢ޽ࠅ‫ޔ‬ᄙߊߩࠕࠫࠕੱ߇࿷૑
㒮ߩ CRC ߪᴦ㛎ᄾ⚂એ೨ߩᲑ㓏߆ࠄᴦ㛎⚳ੌ‫ޔ‬
ߒߡ޿ࠆ‫☨ޔߚ߹ޕ‬࿖ߩࡂࡢࠗᎺࠍ㒰ߌ߫ᣣᧄߦ
⋙ᩏ߹ߢ෸ࠎߢ߅ࠅ‫ޔ‬ᬺോ▸࿐߇ᐢ޿‫ޕ‬
ᦨ߽ㄭ޿⧷⺆ࠍᲣ࿖⺆ߣߔࠆᎿᬺ࿖ߢ޽ࠆ‫ࠣޕ‬
3㧕Q-Pharm ߩ SC ߦߪ⡯ോ⸥ㅀᦠ߇↪ᗧߐࠇߡ޿
ࡠ࡯ࡃ࡞ᴦ㛎ߢ↪޿ࠄࠇࠆၮᧄ↪⺆ߪ⧷⺆ߢ޽
ࠆ߇‫⨶ޔ‬ේ∛㒮ࠍ฽߼ߡᣣᧄߩᴦ㛎ᣉ⸳ߩ CRC
ࠆ‫ޕ‬
ߦߪ⡯ോ⸥ㅀᦠ߇↪ᗧߐࠇߡ޿ࠆߣߎࠈࠍ⷗ߥ
޿‫ޕ‬
ࠝ࡯ࠬ࠻࡜࡝ࠕߩਛߢឭ៤వߣߒߡ․ߦࠢࠗ࡯
4㧕Q-Pharm ߢߪ㧝ߟߩࡈࡠࠕౝߢ࠴࡯ࡓࡔࡦࡃ࡯
ࡦ࠭࡜ࡦ࠼ᄢቇࠍㆬࠎߛߩߪ‫ޔ‬ਥⷐ 3 ㇺᏒߦ޽ࠆක
߇ല₸⊛ߦㅪ៤ߒߡ⹜㛎ᬺോࠍㆀⴕߢ߈ࠆല₸
⮎⑼ቇ㑐ㅪᣉ⸳ߩ੐೨⺞ᩏࠍⴕߞߚ⚿ᨐ‫ߩߎޔ‬ᄢቇ
⊛ߥ⚵❱ㆇ༡૕೙߇ߣࠄࠇߡ޿ࠆ‫৻ޕ‬ᣇ‫⨶ޔ‬ේ
߅ࠃ߮㑐ㅪᣉ⸳ߦ߅ߌࠆක⮎ߩ⎇ⓥ࡮ᢎ⢒૕೙‫ޔ‬ᄢ
∛㒮ߪ‫ޔ‬ᣣᏱ⸻≮ࠍ⋡⊛ߦ૞ࠄࠇߚ⚵❱ㆇ༡૕
ቇ㑐ㅪ∛㒮ߣ⥃ᐥ⹜㛎ᣉ⸳߇ᦨ߽⦟ߊᢛߞߡ߅ࠅ‫ޔ‬
೙ߩਛߢᴦ㛎ᬺോࠍⴕߞߡ޿ࠆߚ߼‫ޔ‬CRC ߦ⺖
౒┙⮎⑼ᄢቇߣߩࡄ࡯࠻࠽࡯ߣߒߡ⋧ᔕߒ޿ߣ್
ߖࠄࠇߡ޿ࠆ㒮ౝߢߩㅪ⛊⺞ᢛ⊛ߥᬺോߪ߆ߥ
ᢿߐࠇߚ߆ࠄߢ޽ࠆ‫ޕ‬
ࠅᄙ޿‫ޕ‬
5㧕Q-Pharm ߩ⹜㛎⽿છකᏧߪ⹜㛎ࡊࡠ࠻ࠦ࡯࡞ߩ
ᧄႎᢥߩౝኈߪᣣᧄߩ⨶ේ∛㒮ߣࠝ࡯ࠬ࠻࡜࡝
ౝኈࠍࠃߊℂ⸃࡮ᛠីߒߡ߅ࠅ‫⥄ޔ‬ಽߩ⸻≮ᬺ
ࠕߩ Q-Pharm ߢߩ⮎‛⥃ᐥ⹏ଔ⹜㛎ߦ߅ߌࠆ CRC
ോߣ Q-Pharm ߢߩ⥃ᐥ⹜㛎ᬺോߣࠍ᣿⏕ߦಽ㔌
ߩᬺോࠍᲧセߒߚ߽ߩߢ޽ࠅ‫ߩߎޔ‬ᬌ⸛⚿ᨐߪᔅߕ
ߐࠇߡ޿ࠆ‫⥃ޕ‬ᐥ⹜㛎ߩ⃻႐ߢߪ⹜㛎ታᣉߦᔀ
ߒ߽ᣣᧄߣࠝ࡯ࠬ࠻࡜࡝ࠕߩ CRC ߩᬺോ৻⥸ߦᄖ
ߒ‫⊒ࠍࡊ࠶ࠪ࡯࠳࡯࡝ޔ‬ើߒߡ߅ࠅ‫ޔ‬CRC ߣߩ
ᝌߢ߈ࠆߣߪ⸒߃ߥ޿‫৻ޔߚ߹ޕ‬ᣇߪ╙Τ, Υ⋧⥃
ㅪ៤߽ࠃ޿‫ޕ‬ᣣᧄߢߪ⸻≮ߣᴦ㛎ࠍหᤨ૬ⴕߐ
ᐥ⹜㛎ࠍਛᔃߣߒߚᴦ㛎ታᣉߩᣉ⸳ߢ޽ࠅ‫ઁޔ‬ᣇߪ
ߖߡ޿ࠆ⹜㛎⽿છකᏧ߇ᄙ޿‫ޕ‬
╙Σ⋧⥃ᐥ⹜㛎߿↢‛ቇ⊛ห╬ᕈ⹜㛎‫⥃ޔ‬ᐥ⮎ℂ⹜
6㧕⮎೷ㇱߦ߅޿ߡߪ‫⮎ޔ‬೷ߩ଻▤࡮ឭଏ࡮▤ℂᠲ
㛎ࠍฃ⸤ߒߡታᣉߔࠆᯏ㑐ߥߩߢ‫⥃ޔ‬ᐥ⹜㛎ታᣉߩ
૞ߪ⨶ේ∛㒮ߩᴦ㛎ߦ߅ߌࠆࠃࠅ◲⇛ൻߐࠇߡ
ⅣႺߦߪ⇣ߥࠆ஥㕙߇޽ࠆ‫⹜ޔߒ߆ߒޕ‬㛎ߩ⒳㘃߇
޿ࠆ‫ޕ‬
⇣ߥߞߡ޿ߡ߽ GCP ߦᴪߞߚ⑼ቇᕈ߿୶ℂᕈ‫⹜ޔ‬
㛎ߦ߅ߌࠆ CRC ߩᓎഀ߿⽿છߥߤߦߪ౒ㅢὐ߇ᭂ
Q-Pharm ߩ SC ߣ⨶ේ∛㒮ߩ CRC ߩᬺോᲧセߦ
߼ߡᄙ޿ߩߢ‫ޔ‬ᢓ߃ߡߘߩታോ⁁ᴫࠍᲧセᬌ⸛ߒ‫ޔ‬
㑐ㅪߒߡ‫ޔ‬వߕᶏᄖߣᣣᧄߩ CRC ߩᚑ┙ߦ⥋ࠆᱧ
ᣣᧄߦ߅ߌࠆᴦ㛎ߩല₸ൻ߿ࠣࡠ࡯ࡃ࡞ൻߦ CRC
ผࠍㄡߞߡߺߚ‫ޕ‬CRC ߪ 1970 ᐕᓟඨߦ☨࿖ߢ↢߹
ߣ޿߁஥㕙߆ࠄߤߩࠃ߁ߦ⽸₂ߢ߈ࠆ߆ࠍᬌ⸛ߔ
ࠇ‫ޔ‬એᓟ⷏᰷⻉࿖ߦ߽᥉෸ߒ‫ޔ‬ቯ⌕ߔࠆߦ⥋ߞߚᣂ
ࠆߎߣߣߒߚ‫ޕ‬
ߒ޿⡯⒳ߢ޽ࠆ‫ޕ‬CRC ዉ౉એ೨ߩ⥃ᐥ⎇ⓥߢߪ‫ޔ‬
੹࿁ߩᣣᧄ‫ࠕ࡝࡜࠻ࠬ࡯ࠝޔ‬ฦ 1 ᣉ⸳ߩ⥃ᐥ⹜㛎
⎇ⓥߦଥࠆᬺോߩᱴߤࠍ⥃ᐥ⎇ⓥ⠪⥄り߇ⴕߞߡ
ߩታᣉ⁁ᴫߩᲧセᬌ⸛ߩ⚿ᨐ߆ࠄߪᰴߩὐ߇ᜰ៰
޿ߚ‫⎇ߒ߆ߒޕ‬ⓥߩౝኈ߿ᚻ㗅߇ⶄ㔀ൻߒ‫ޔ‬㒮ౝ࡮
ߐࠇߚ‫ޕ‬
ᄖߩઁㇱ⟑ߩදജ߇ᔅⷐߣߐࠇࠆߦᓥ޿‫ޔ‬කᏧߦ
1㧕Q-Pharm ߦ߅ߌࠆ SC ߩ⽿ോߪ⹜㛎⽿છකᏧߩ
ߣߞߡりㄭߥሽ࿷ߢ޽ࠆ⋴⼔Ꮷ╬߇කᏧߩ⥃ᐥ⎇
⵬૒ᓎߣߒߡ⹜㛎ߩࠦ࡯࠺ࠖࡀ࡯࠻߿ࡑࡀࠫࡦ
ⓥࠍ⵬૒ߔࠆࠃ߁ߦߥߞߡ߈ߚ‫⥄ߦ߁ࠃߩߎޕ‬ὼ⊒
ࠣࠍⴕ߁ߎߣߢ޽ࠅ‫ࠍࠇߘޔ‬ਥ૕⊛⢻േ⊛ߦ⥃
↢⊛ߦ⋴⼔ᏧߦࠃࠆකᏧߩ⥃ᐥ⎇ⓥߩ⵬ഥᬺോ߇
ᐥ⹜㛎ࠍⴕߞߡ޿ࠆ‫ߦࠇߘޕ‬ኻߒ‫⨶ޔ‬ේ∛㒮ߦ
৻⥸ൻߒߚ߇‫ޔߦᦝޔ‬කቇ⊛ߥᬺോߣකቇએᄖߩᬺ
߅ߌࠆ CRC ߪ⹜㛎⽿છකᏧߩᜰ␜ਅߦᴦ㛎ߦ
ോ߇ಽᜂߐࠇߚߎߣ߇ CRC ߣ޿߁⡯⒳ߩ↢޿┙ߜ
දജߔࠆߣ޿߁ฃേ⊛ߥ┙႐ߦ⇐߹ߞߡ޿ࠆ⁁
ߣ޿ࠊࠇߡ޿ࠆ 3㧕‫ޕ‬
9/12
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
47
Kobayashi A et al.
ᓥߞߡ⃻࿷⷏᰷⻉࿖ߢߪ CRC ࠍᴦ㛎ߦ㒢ቯߔࠆ
ࡀࠫࡔࡦ࠻ߒࠦ࡯࠺ࠖࡀ࡯࠻ߔࠆߎߣߦࠃࠅ⹜㛎
ߎߣߥߊ‫ޔ‬ᐢߊ⥃ᐥ⎇ⓥ߿⥃ᐥ⹜㛎ߦข౉ࠇߡ޿ࠆ
ࠍ౞Ṗߦㅴ߼ࠆ⡯⒳ߣℂ⸃ߐࠇࠆࠃ߁ߥ⺑᣿ࠍߒ
ࠃ߁ߢ޽ࠆ‫ޕ‬Q-Pharm ߦ߅ߌࠆฃ⸤⹜㛎߽ᴦ㛎ߢ޽
ߡ޿ࠆ‫੹ޕ‬࿁ߩ⺞ᩏߩ⚿ᨐߦࠃࠇ߫‫ޔ‬CRC ߩᓎഀ
ࠆ߆⥃ᐥ⮎ℂ⊛⎇ⓥߢ޽ࠆ߆ࠍ໧ࠊߕ CRC ߇㑐ਈ
ߦ㑐ࠊࠆଏㅀߩ⻉⸥ㅀߩਛߢ‫ޔ‬ਛ㊁ࠄߩ CRC ߦ㑐
ߒߡ޿ࠆ‫ޕ‬ᣣᧄߢߪㆊ෰ߦᴦ㛎ߩߺࠍኻ⽎ߣߒߡ
ߔࠆቯ⟵ߠߌ߇ Q-Pharm ߩ SC ߩ⡯ോ⸥ㅀᦠߩ⸥タ
GCP ࠍዉ౉ߒߚߣ޿߁⚻✲߇޽ࠅ‫ޔ‬ᴦ㛎ࠍ⥃ᐥ⎇
ౝኈ߿ታ૕ߦᦨ߽ㄭ޿‫⨶ޕ‬ේ∛㒮ߦ߅ߌࠆ CRC ߪ‫ޔ‬
ⓥߩ৻ㇱߢ޽ࠆߣ޿߁⷗ᣇࠍߣࠄߕߦ․೎ᛒ޿ߒ
ߘߩታᣉᬺോߩౝኈߪߎߩ⸥ㅀߦㄭ޿߽ߩߩ‫ޔ‬⡯⽿
ߡ޿ࠆᣉ⸳߇ᄙ޿‫⨶ޕ‬ේ∛㒮ߢ߽ᣂ⮎ߩᴦ㛎ߣ⥃ᐥ
㕙ߢߪਥ૕⊛⢻േ⊛ߦᴦ㛎ࠍࡑࡀࠫࡔࡦ࠻ߒ‫࡯ࠦޔ‬
⎇ⓥ⊛ߥ⹜㛎ߣࠍ඙೎ߒߡขᛒߞߡ߅ࠅ‫⥃ޔ‬ᐥ⎇ⓥ
࠺ࠖࡀ࡯࠻ߔࠆ┙႐ߣߒߡ⹺⼂ߐࠇߡ޿ࠆ߆ߤ߁
⊛ߥ⹜㛎ߦߪ CRC ߪ㑐ਈߒߡ޿ߥ޿‫ޕ‬
߆ߦߪ⇼໧߇޽ࠆ‫ޕ‬
ᣣᧄߩᴦ㛎ߦ CRC ߇⊓႐ߒߚߩߪ 1997 ᐕߦ GCP
ߎ߁ߒߚ CRC ߦ㑐ࠊࠆᓸᅱߥ⋧㆑ߪ CRC ߣ޿߁
߇೙ቯߐࠇߡ߆ࠄߢ޽ࠆ‫ ߒ߆ߒޕ‬GCP ߦ㑐ࠊࠆ⻉
⡯⒳߇ᒻᚑߐࠇࠆㆊ⒟ߩ㆑޿ߦ৻࿃ߒߡ޿ࠆࠃ߁
ᢥᦠߦߪᴦ㛎ࠦ࡯࠺ࠖࡀ࡯࠲࡯㧔CRC㧕ߣ޿߁⸒⪲
ߦᕁࠊࠇࠆ‫⷏ޔࠅ߹ߟޕ‬᰷ߢߪ CRC ߪකቇ⊛ౝኈ
ߪߥ޿‫ޕ‬GCP ⋭઎╙ 2 ╙ 14 㗄ߦࠃࠇ߫ CRC ߪ‫ޟ‬ᴦ
એᄖߩᬺോࠍਛᔃߦข⚵ߺ‫ޔ‬ਥ૕⊛࡮⢻േ⊛ߦ⹜㛎
㛎දജ⠪‫ߩޠ‬㧝ߟߣ૏⟎ߠߌߐࠇ‫ߩߘޔ‬ᓎഀߪ㨬ታ
ታᣉࠍㆇ༡ߒ‫ޔ‬ᔅⷐߥ⺞ᢛࠍⴕ߁ߣ޿߁⡯⒳ߣߒߡ
ᣉක≮ᯏ㑐ߦ߅޿ߡᴦ㛎⽿છකᏧ߹ߚߪᴦ㛎ಽᜂ
⥄ὼ⊒↢⊛ߦ⏕┙ߒߡ޿ߞߚߩߦኻߒ‫ޔ‬ᣣᧄߢߪ߹
කᏧߩᜰዉߩਅߦߎࠇࠄߩ⠪ߩᴦ㛎ߦଥࠊࠆᬺോ
ߛᴦ㛎ߦ߅޿ߡߘ߁ߒߚ⡯⒳ࠍฃߌ౉ࠇࠆ࿯ფⅣ
ߦදജߔࠆ⮎೷Ꮷ࡮⋴⼔Ꮷߘߩઁߩක≮㑐ଥ⠪ࠍ޿
Ⴚ߇㉯ᚑߐࠇߥ޿߹߹ߦ GCP ࠍᴺ೙ൻߒߚߎߣ‫ޔ‬
߁㨭ߣቯ⟵ߐࠇߡ޿ࠆ‫⺖ߦᦝޕ‬㐳ㅢ⍮㧔ᐔᚑ 9 ᐕ㧕
ߘߒߡ‫ޟ‬ᴦ㛎දജ⠪‫ᦌ߁޿ߣޠ‬ᤒߥฬ⒓ߢ⹜㛎⽿છ
ߢߪ‫ޟ‬ታᣉක≮ᯏ㑐ߦ߅޿ߡᴦ㛎ࠍታᣉߔࠆ࠴࡯ࡓ
කᏧߩᜰዉߩၮߦᴦ㛎ߦදജߔࠆࠬ࠲࠶ࡈߣ޿߁
ߩࡔࡦࡃ࡯ߢᴦ㛎⽿છකᏧߦࠃߞߡᜰዉ࡮⋙〈ߐࠇ‫ ޔ‬૏⟎ߠߌߢᣣᧄߩක≮⃻႐ߦዉ౉ߖߑࠆࠍᓧߥ
ኾ㐷⊛┙႐߆ࠄᴦ㛎⽿છකᏧ෸߮ᴦ㛎ಽᜂකᏧߩ
߆ߞߚ‫ߡߒߘޕ‬⡯⢻ࠍ⷗⋥ߔᯏળ߇ߥ޿߹߹ߦ⃻࿷
ᬺോߦදജߔࠆ⠪ߢ޽ࠆ‫ޔߦᦝޕࠆ޿ߡߞߥߣޠޕ‬
ߦ⥋ߞߡ޿ࠆ߽ߩߣ⠨߃ࠄࠇߚ‫ޕ‬
ෘ↢⑼ቇ⎇ⓥ‫ޟ‬ᣂ GCP ᥉෸ቯ⌕✚ว⎇ⓥ‫ޠ‬ႎ๔ᦠ
⨶ේ∛㒮ߦ߅ߌࠆ CRC ߦ㗫ᐲ㜞ߊ↢ߓࠆᬺോߦ
㧔ᐔᚑ 9 ᐕᐲ㧕ߦߪ CRC ߪᬺോߣߒߡ‫⋥ޟ‬ធ⊛ߦ
ߪᣉ⸳ౝߢߩㅪ⛊⺞ᢛߩ઀੐߇޽ࠆ‫ߚߒ߁ߎޕ‬ᬺോ
ߪᴦ㛎⽿છකᏧࠍᡰេߔࠆᬺോࠍⴕ߁‫ޔࠅ߹ߟޕ‬ක
߇ᄙߊ⊒↢ߔࠆℂ↱ߩ㧝ߟߣߒߡ‫ޔ‬ᣣᏱ⸻≮ߩߚ߼
⮎ຠߩ⥃ᐥ⹜㛎ታᣉㆊ⒟ߦ߅޿ߡ‫ⵍߌࠊࠅߣޔ‬㛎⠪
ߩ⚵❱ㆇ༡૕೙ߩਛߦᴦ㛎߇⚵౉ࠇࠄࠇߡ޿ࠆߎ
ߣᴦ㛎ߣߩ⺞ᢛࠍⴕ޿‫ޔ‬ᴦ㛎ߩ୶ℂᕈ‫⑼ޔ‬ቇᕈࠍ଻
ߣ߇᜼ߍࠄࠇࠃ߁‫ޕ‬Q-Pharm ߢߪ⹜㛎ታᣉ↪ߦ૞ࠄ
⸽ߔࠆߚ߼ߦᵴേࠍⴕ߁‫⺑ߣޠ‬᣿ߐࠇߡ޿ࠆ‫৻ޕ‬ᣇ‫ޔ‬
ࠇߚ⚵❱ߩਛߢㆇ༡ߐࠇࠆߎߣ߇‫ߚߒ߁ߎޔ‬ㅪ⛊⺞
ਛ㊁ࠄߪ CRC ࠍ‫ޟ‬ᴦ㛎ᜂᒰකᏧ࡮ᴦ㛎ଐ㗬⠪࡮ⵍ
ᢛᬺോࠍᄢ᏷ߦᷫࠄߒߡ޿ࠆ㧝ߟߩᄢ߈ߥℂ↱ߣ
㛎⠪ߩ㑆ߦ౉ߞߡ‫ߡߒ࠻࡯ࡀࠖ࠺࡯ࠦޔ‬ᴦ㛎㧔⥃ᐥ
ᕁࠊࠇࠆ‫ޕ‬ᣣᧄߩᴦ㛎ߦ߅޿ߡ CRC ߪᴦ㛎㐿ᆎએ
⹜㛎ߦ฽߹ࠇࠆ㧕߇౞Ṗߦㅴ߻ࠃ߁ߦᡰេߔࠆᓎഀ
೨߆ࠄ㑐ࠊࠅ‫ੌ⚳ޔ‬ႎ๔ᦠߩ૞ᚑߦ⥋ࠆ߹ߢ‫ߣ߶ޔ‬
ࠍᜂߞߡ߅ࠅ‫ߩߘޔ‬ਥߥᡰេᬺോߪ‫ޔ‬Ԙో૕ߩ⺞ᢛ
ࠎߤߩᬺോߦ㑐ߞߡ޿ࠆ‫৻ߩߘޕ‬ᣇ‫ޔ‬ᣣᧄߦ߅ߌࠆ
ᓎ‫ޔ‬ԙⵍ㛎⠪ߩࠤࠕ‫ޔ‬Ԛᴦ㛎ᜂᒰකᏧߩᡰេ‫ࠃ߅ޔ‬
ᴦ㛎ߩᮡḰᬺോᚻ㗅ᦠ (SOP) ߦߪ㒮㐳ߣ⹜㛎⽿છ
߮‫ޔ‬ԛᴦ㛎ଐ㗬⠪߳ߩኻᔕߢ޽ࠆ‫ౕߣޠ‬૕⊛ߦߘߩ
කᏧߩᬺോߪ᣿⸥ߐࠇߡ޿ࠆ߽ߩߩ‫ޔ‬SOP ߦ␜ߐࠇ
ᓎഀߣᬺോౝኈࠍ᜼ߍߡ޿ࠆ
4㧕5㧕
ߡ޿ࠆᬺോߩᄢඨߦ㑐ࠊࠆ CRC ߩᬺോߪ᣿␜ߐࠇ
‫ޕ‬
⸒޿឵߃ࠇ߫‫⋭ޔ‬઎ GCP ߢߪ CRC ࠍ‫ޟ‬ᴦ㛎ࠍਥ
ߚᢥᦠ߇ߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫৻ޕ‬ᣇ‫ޔ‬Q-Pharm ߦ߅
૕⊛ߦㅴ߼ࠆ⹜㛎⽿છ㧔ᜂᒰ㧕කᏧߩᜰ␜ߦᓥ޿‫ޔ‬
޿ߡ߽ SOP ߦ SC ߩᬺോߩ⸥タߪߥ޿߇‫ޔ‬⡯ോ⸥ㅀ
කᏧࠍᡰេߔࠆ‫⵬߁޿ߣޠ‬ഥ⊛߆ߟฃりߩ┙႐ߣߒ
ᦠߦࠃࠅᬺോߣ⽿છ߇᣿␜ߐࠇߡ޿ࠆ‫߇ࠊޕ‬࿖ߦ߅
ߡߩ⦡ว޿߇ᒝ޿߇‫ޔ‬ਛ㊁ࠄߪ CRC ࠍ߻ߒࠈਥ૕
޿ߡߪ Q-Pharm ߽฽߼ߡ⷏᰷⻉࿖ߣߪ⇣ߥࠅ‫⋴ޔ‬
⊛⢻േ⊛ߥ┙႐ߢ‫⹜ޔ‬㛎⽿છ⠪ࠍ⵬૒ߒߡ⹜㛎ࠍࡑ
⼔Ꮷ‫⮎ޔ‬೷Ꮷ‫⥃ޔ‬ᐥᬌᩏᛛᏧߣ޿߁⇣ߥࠆ⍮⼂ߣᛛ
48
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
10/12
原著論文
⢻ࠍ߽ߟᛛⴚ⠪߇ CRC ࠍൕ߼ࠆ⁁ᴫߥߩߢ‫ࠇߘޔ‬
1㧕Q-Pharm ߢߪ SC ߪ⹜㛎⽿છකᏧߩ⵬૒ᓎߣߒ
ߙࠇߩᛛ⢻ߦᔕߓߡ⡯ോߣ⽿છࠍ⡯ോ⸥ㅀᦠߥߤ
ߡਥ૕⊛⢻േ⊛ߦ⥃ᐥ⹜㛎ࠍࡑࡀࠫࡔࡦ࠻ߒ‫⹜ޔ‬
ߢ᣿⏕ൻߒ‫ޔ‬⢻േ⊛ߦ⥃ᐥ⹜㛎ࠍㅴ߼ࠆࠃ߁ߦ࿑ࠆ
㛎ߩ౞Ṗߥታᣉߦദ߼ߡ޿ߚ‫৻ޕ‬ᣇ‫⨶ޔ‬ේ∛㒮ߦ
ߎߣߪ‫߇⾰ޔ‬㜞ߊ‫ޔ‬౞Ṗ߆ߟല₸⊛ߥ⥃ᐥ⹜㛎ߩታ
߅ߌࠆ CRC ߪ⹜㛎⽿છකᏧᜰ␜ਅߦᴦ㛎ߦදജ
ᣉߦ❬߇ࠆߣᕁࠊࠇࠆ‫ޕ‬
ߔࠆߣ޿߁ฃേ⊛ߥ┙႐ߦㄭ޿ߣᕁࠊࠇߚ‫ޕ‬
⹜㛎⮎೷ߩ⺞೷ߣ▤ℂ߇߭ߣࠅߩ⮎೷Ꮷߦછߐ
2㧕Q-Pharm ߩ SC ߣ⨶ේ∛㒮ߩ CRC ߩᬺോ߳ߩข
ࠇߡ޿ࠆߣ޿߁੐ታߪ੍ᦼߖߧߎߣߢ޽ߞߚ‫⨶ޕ‬ේ
⚵ߺߩ㆑޿ߪ‫ޔ‬᰷☨ߢߪ⥃ᐥ⹜㛎ߦ߅޿ߡ⋴⼔Ꮷ
∛㒮ߢߪ⺋ᛩਈࠍ㒐ߋߚ߼ߦ⮎೷Ꮷߦࠃࠆ⺞೷ߩ
߇⹜㛎ታᣉ⠪ߩ⵬૒ߩᓎഀࠍᜂ޿‫⥄ޔ‬ὼ⊒↢⊛ߦ
࠳ࡉ࡞࠴ࠚ࠶ࠢߪᰳ߆ߖߥ޿‫ޔߒ߆ߒޕ‬Q-Pharm ߢ
⻉૞ᬺࠍಽᜂߔࠆߦ⥋ߞߚߩߦኻߒ‫ޔ‬ᣣᧄߢߪᴦ
ߪ⺋ᛩਈࠍ㒐ߋߚ߼ߦ⮎೷Ꮷ߇޿ࠈ޿ࠈߥᎿᄦࠍ
㛎ߩⅣႺ߿૕೙߇ᢛ߁ߦవ┙ߜ GCP ߦࠃࠅ CRC
ߒߡ޿ࠆ⁁ᴫ߇ⷰኤߢ߈ߚ‫⺋ޕ‬ᛩਈࠍߒߥ޿ߎߣ߇
ࠍ‫ޟ‬ᴦ㛎දജ⠪‫ߡߒߣޠ‬૏⟎ߠߌߚߣ޿߁ᱧผ⊛
ᒰὼߩ૶๮ߢ޽ࠆ⮎೷Ꮷߣ޿߁⾗ᩰ߇⹺⍮ߐࠇߡ
⢛᥊ߦ⽶߁ߣߎࠈᄢ߈޿ߣ⠨߃ࠄࠇߚ‫࠻ࠬ࡯ࠝޕ‬
޿ࠆߎߣ߽ߎ߁ߒߚ◲⇛ൻࠍኈ⹺ߒߡ޿ࠆ⢛᥊ߦ
࡜࡝ࠕߢߪᱴߤߔߴߡߩ SC ߪ⋴⼔Ꮷߢ޽ߞߚ߇‫ޔ‬
޽ࠆߩߢߪߥ޿߆ߣᕁࠊࠇߚ‫ޕ‬
ᣣᧄߢߪ⋴⼔Ꮷ‫⮎ޔ‬೷Ꮷ‫⥃ޔ‬ᐥᬌᩏᛛᏧߥߤߢ޽
ࠆ‫ޕ‬
ߥ߅‫ᧄޔ‬ႎᢥߪ⹜㛎ࠍฃ⸤ߒߡታᣉߔࠆࠝ࡯ࠬ࠻
࡜࡝ࠕߩ 1 ᣉ⸳ߣᣣᧄߩ⨶ේ∛㒮ߣߩ⥃ᐥ⹜㛎ታ
3㧕Q-Pharm ߩ SC ߪਥߣߒߡ⹜㛎㐿ᆎએᓟߩᬺോ
ᣉ⁁ᴫࠍᲧセߒߚ߽ߩߢ޽ࠆ‫ޕ‬ᓥߞߡ‫⺞ᧄޔ‬ᩏߩ⚿
ߦ៤ࠊߞߡ޿ࠆߦኻߒ‫⨶ޔ‬ේ∛㒮ߩ CRC ߩᬺോ
ᨐࠍએߞߡࠝ࡯ࠬ࠻࡜࡝ࠕో૕ߩᴦ㛎ࠍ⺰ߕࠆߎ
ߪᴦ㛎ᄾ⚂✦⚿એ೨߆ࠄᴦ㛎⚳ੌᓟߩ⋙ᩏߦ߹
ߣߦߪήℂ߇޽ࠆ‫ޕ‬ૉߒ‫੹ޔ‬࿁Ყセᬌ⸛ߒߚ 2 ᣉ⸳
ߢ෸ࠎߢ߅ࠅ‫▸ޔ‬࿐ߪᐢ߆ߞߚ‫ޕ‬
ߩ⹜㛎ታᣉߩ⢛᥊߿ⅣႺߪ⇣ߥࠆߣߪ⸒߃‫⑼ޔ‬ቇᕈ
4㧕Q-Pharm ߢߪ SC ߦኻߔࠆ⡯ോ⸥ㅀᦠ߇↪ᗧߐ
ߣ୶ℂᕈࠍᜂ଻ߒߟߟ‫⹜ޔ‬㛎ࠍല₸⊛ߦㅴ߼ࠆߣ޿
ࠇߡ߅ࠅ‫ߩߘޔ‬છോߣߒߡ⹜㛎⽿છකᏧࠍ⵬૒ߒ
߁ὐߢߪෳ⠨ߣߔߴ߈ὐߪᄙ޿ߣᕁࠊࠇߚ‫ޕ‬
ߡ⹜㛎ࠍ⥄ਥ⊛ߦࡑࡀࠫࡔࡦ࠻ߒ‫ࡦࡔࡓ࡯࠴ޔ‬
Q-Pharm ߪ RBH ∛㒮⟲ౝߩ 1 ⥃ᐥ⹜㛎ฃ⸤ᯏ㑐ߢ
ࡃ࡯ߣߩࠦ࡯࠺ࠖࡀ࡯࠻ߔࠆߎߣ߇᣿⸥ߐࠇߡ
޽ࠆ߇‫∛ߩߎޔ‬㒮⟲ߩਛߢߪᢙᄙߊߩ╙Τ㨪Φ⋧⥃
޿ߚ‫ޕ‬ᣣᧄߦ߅޿ߡ߽ CRC ߦኻߔࠆ⡯ോ⸥ㅀᦠ
ᐥ⹜㛎߇ታᣉߐࠇߡ߅ࠅ‫࡞ࡃ࡯ࡠࠣޔ‬ᴦ㛎߽ᄙߊ฽
ࠍ૞ᚑߔࠆߎߣߪᴦ㛎ߩല₸ะ਄ߦ❬߇ࠆน⢻
߹ࠇࠆߣᕁࠊࠇࠆ‫ޕ‬ᓥߞߡ‫ޔ‬RBH ∛㒮⟲ౝߩࠢ࡝
ᕈ߇޽ࠆߣ⠨߃ࠄࠇߚ‫ޕ‬
࠾࠶ࠢߢ੹࿁ߣห᭽ߦ╙Τ‫ޔ‬Υ⋧⥃ᐥ⹜㛎ߩታᣉ⁁
3. ᴦ㛎ߩࠣࡠ࡯ࡃ࡞ൻߪ߹ߔ߹ߔㅴࠎߢ߅ࠅ‫ޔ‬ᣣ
ᴫࠍ⺞ᩏߒ‫ޔ‬ᣣᧄߩᴦ㛎ߩታᣉ⁁ᴫߣᲧセᬌ⸛ߔࠇ
ᧄߪߘߩᵹࠇߦขࠅᱷߐࠇߟߟ޽ࠆ‫♽⮎ޕ‬ᄢቇߦ
߫‫੹ߦᦝޔ‬ᓟߩᣣᧄߩᴦ㛎ߩല₸ൻߣࠣࡠ࡯ࡃ࡞ൻ
߅޿ߡ⥃ᐥ⹏ଔߩቇⴚߣᢎ⢒ᵴേࠍዷ㐿ߔࠆߎ
߳ߩ␜ໂ߇ᓧࠄࠇࠆߣ⠨߃ࠆ‫ޕ‬
⚿⺆
1. ࠢࠗ࡯ࡦ࠭࡜ࡦ࠼ᄢቇ㑐ㅪߩ⥃ᐥ⮎ℂ⹜㛎ฃ⸤
ᯏ㑐 Q-Pharm ߦṛ࿷ߒ‫ߌ߅ߦࠕ࡝࡜࠻ࠬ࡯ࠝޔ‬
ࠆ⥃ᐥ⹜㛎ߩታᣉ⁁ᴫࠍⷰኤ࡮⺞ᩏߒߚ‫ޔߚ߹ޕ‬
ߘߩ⚿ᨐߦၮߠ߈⨶ේ∛㒮ߣ Q-Pharm ߦ߅ߌࠆ
⹜㛎ታᣉࠍ CRC
㧔ࠝ࡯ࠬ࠻࡜࡝ࠕߢߩ๭⒓ߪ SC㧕
ߩⷰὐ߆ࠄᲧセߒߚ‫ޕ‬
౮⌀ 5 Q㧙Pharm ࠃࠅਈ߃ࠄࠇߚୃੌ⸽
㧔╙㧝ภ㧕
2. Ყセᬌ⸛ߩ⚿ᨐ߆ࠄߪᰴߩ⻉ὐ߇ᜰ៰ߐࠇߚ㧦
11/12
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
49
Kobayashi A et al.
ᦨᓟߦߎߩ⎇ୃࠍᄢቇ㒮 GP ߩ৻Ⅳߣߒߡታ⃻ߒ
ߣߪ‫ޔ‬ᴦ㛎ߩࠣࡠ࡯ࡃ࡞ൻߦᔕ߃ࠄࠇࠆੱ᧚ߩ⢒
ߡ޿ߚߛ޿ߚᦸ᦬ᱜ㓉ቇ㐳‫ߦ߮ࠄߥޔ‬࿖㓙੤ᵹ࠮ࡦ
ᚑߦነਈߔࠆ‫ޕ‬
4. ᧄ⺞ᩏߢߪᣣᧄߩ╙Τ㨪Φ⋧⥃ᐥ⹜㛎ታᣉᣉ⸳
࠲࡯㐳࡮⩲ኅ↭ሶᢎ᝼‫╩ޔ߮ࠃ߅ޔ‬⠪ࠍฃߌ౉ࠇߡ
ߣࠝ࡯ࠬ࠻࡜࡝ࠕߩ⥃ᐥ⮎ℂ⹜㛎ታᣉᣉ⸳ߣߩ
޿ߚߛ޿ߚ Q-Pharm ߩ Hooper ␠㐳‫ޔ‬ਗ߮ߦ CSDD
⹜㛎ታᣉߩ⁁ᴫࠍᲧセߒߚ߇‫੹ޔ‬ᓟ‫ޔ‬ਔ࿖ߩ╙Τ
ߩ Dickinson ᚲ㐳ߦᗵ⻢޿ߚߒ߹ߔ‫ޕ‬
㨪Υ⋧⥃ᐥ⹜㛎ߩታᣉ⁁ᴫࠍᲧセߔࠆߎߣߪ‫ޔ‬ᣣ
ᧄߩᴦ㛎ߩല₸ะ਄ߣࠣࡠ࡯ࡃ࡞ൻߩߚ߼ߩ᦭
ᒁ↪ᢥ₂
⋉ߥᖱႎߩឭଏߦ❬߇ࠆ߽ߩߣ⠨߃ࠄࠇࠆ‫ޕ‬
1㧕Tyer, J.H., Eadie, M.J., Sutherland, J.M., Hooper,
⻢ㄉ
W.D., Outbreak of anticonvalsant intoxication in an
Australian city. Brit. Med. J. 4, 271-273 (1970)
੹࿁ߩታോ⎇ୃߪ╩⠪ߦߣߞߡߪ޽ࠄࠁࠆ߽ߩ
2㧕⍹ᯅᘮᄥ‫ޔ‬
‫ޟ‬ᣣᧄࠍ฽߻࿖㓙౒หᴦ㛎ታᣉ⁁ᴫ‫ޔޠ‬
᡽╷⎇࠾ࡘ࡯ࠬ No.21, 18-21 (2006)
߇ೋ߼ߡߩ૕㛎ߢ޽ߞߚ߇‫ࠍࠇߎޔ‬ᴛጊߩੱߚߜ߇
ᡰ߃ߡߊࠇߚ‫ޕ‬Q-Pharm ߩࠬ࠲࠶ࡈߩᣇ‫⾰ߩ⑳ߪޘ‬
3㧕M-R Mueller, From delegation to specialization:
໧ߦᔟߊ╵߃ߡߊࠇߚߒ‫ࠗ࠹ࠬࡓ࡯ࡎޔ‬వߩ
nurse and clinical trial co-ordination. Nursing
Monique ߣ Yoland ߥߤ‫ޔ‬಴ળ߁ੱߚߜߪ⊝ⷫಾߛߞ
Inquiry 8: 182 – 190 (2001)
ߚ‫ޕ‬ᣣᧄ⺆ࠍ⠌޿ᆎ߼ߡߊࠇߚࠬ࠲࠶ࡈ߽޿ߚ‫ޕ‬ᡷ
4㧕‫ޟ‬ක⮎ຠߩ⥃ᐥ⹜㛎ߣ CRC‫ୃ⋙ޔޠ‬㧦㧔⽷㧕ᣣᧄ
߼ߡᓮ␞ࠍ↳ߒ਄ߍߚ޿‫ޕ‬൩⺰ೋ߼ߡߩᵷ㆜ߛߞߚ
⮎೷Ꮷ⎇ୃ࠮ࡦ࠲࡯‫✬ޔ‬㓸㧦ਛ㊁㊀ⴕ‫ޔ‬ᄢᴰ੩
ߚ߼ߦᄢᄌߥߎߣߪጊߩࠃ߁ߦ޽ߞߚ߇‫ޔ‬㧝ߟ㧝ߟ
ሶ‫ޔᤩ ⼱␹ޔ‬㊁ญ㓉ᔒ‫⮎ޔ‬੐ᣣႎ␠㧔2001 ᐕ㧕
⸃᳿ߒߡ޿ߞߚᩮᕈߣήᚒᄞਛߢㆊߏߒߚᣣ‫ߪޘ‬
5㧕ක≮࡮∛㒮▤ℂ↪⺆੐ౖ㧔ᡷቯ╙ 3 㧕
‫ޔ‬ᣣᧄ∛
ᣣᧄߦዬߚࠄ᳿ߒߡ⚻㛎ߔࠆߎߣߩߢ߈ߥ޿లታ
㒮▤ℂቇળቇⴚᖱႎᆔຬળ✬‫ࡖࠫ࡮ࠕࡆ࠮࡞ࠛޕ‬
ᗵߢ޽ߞߚߣ⏕ାߒߡ޿ࠆ‫ޕ‬
ࡄࡦ㧔2006 ᐕ㧕‫ޕ‬
50
J Kyoritsu Univ Pharm 2007. 10 Vol. 3
12/12
Fly UP